Gadsden Properties (GADS) 10-K 17 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 14, 2014	Jun. 28, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'PHOTOMEDEX INC	'	'
Entity Central Index Key	'0000711665	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$188,839,761
Entity Common Stock, Shares Outstanding	'	18,903,245	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$45,388	$44,348
Short term bank deposit	14,113	18,000
Accounts receivable, net of allowance for doubtful accounts of $10,734 and $6,917, respectively	27,218	19,064
Inventories, net	27,547	22,467
Deferred tax asset	13,041	19,441
Prepaid expenses and other current assets	12,597	12,853
Total current assets	139,904	136,173
Property and equipment, net	10,489	6,759
Patents and licensed technologies, net	10,832	12,673
Other intangible assets, net	9,701	10,854
Goodwill, net	24,930	24,500
Deferred tax asset	24,039	20,186
Funds in respect of employee rights upon retirement and other assets	1,034	745
Total assets	220,929	211,890
Current liabilities:	'	'
Current portion of notes payable	838	609
Short term debt	10,000	10
Accounts payable	14,785	10,025
Accrued compensation and related expenses	3,230	2,494
Other accrued liabilities	22,032	22,099
Deferred revenues	5,961	5,259
Total current liabilities	56,846	40,496
Long-term liabilities:	'	'
Notes payable, net of current maturities	82	0
Deferred revenues	2,758	3,313
Other liabilities	61	166
Liability for employee rights upon retirement	821	588
Total liabilities	60,568	44,563
Commitment and contingencies (Note 10)	'	'
Stockholders' Equity:	'	'
Preferred Stock, $.01 par value, 5,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2013 and 2012	0	0
Common Stock, $.01 par value, 50,000,000 shares authorized; 18,903,245 and 21,043,947 shares issued and outstanding, respectively	189	210
Additional paid-in capital	104,954	130,954
Retained earnings	53,679	35,302
Accumulated other comprehensive income	1,539	861
Total stockholders' equity	160,361	167,327
Total liabilities and stockholders' equity	$220,929	$211,890

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Accounts receivable, allowance for doubtful accounts	$10,734	$6,917
Stockholders' Equity	'	'
Preferred Stock, par value (in dollars per share)	$0.01	$0.01
Preferred Stock, authorized (in shares)	5,000,000	5,000,000
Preferred Stock, issued (in shares)	0	0
Preferred Stock, outstanding (in shares)	0	0
Common Stock, par value (in dollars per share)	$0.01	$0.01
Common Stock, authorized (in shares)	50,000,000	50,000,000
Common Stock, issued (in shares)	18,903,245	21,043,947
Common Stock, outstanding (in shares)	18,903,245	21,043,947

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]	'	'	'
Revenues	$224,664	$220,651	$132,082
Cost of revenues	45,035	46,642	26,296
Gross profit	179,629	174,009	105,786
Operating expenses:	'	'	'
Engineering and product development	3,306	2,914	1,057
Selling and marketing	127,528	116,487	62,185
General and administrative	26,750	27,330	45,192
Total operating expenses	157,584	146,731	108,434
Operating profit (loss)	22,045	27,278	-2,648
Other income (loss):	'	'	'
Interest and other financing income (expense), net	702	-351	-68
Income (loss) before income tax (expense) benefit	22,747	26,927	-2,716
Income tax (expense) benefit	-4,370	-4,438	2,022
Net income (loss)	18,377	22,489	-694
Net income(loss) per share (Note 1):	'	'	'
Basic (in dollars per share)	$0.90	$1.10	($0.06)
Diluted (in dollars per share)	$0.89	$1.08	($0.06)
Shares used in computing net income (loss) per share:	'	'	'
Basic (in shares)	20,454,970	20,355,520	11,602,049
Diluted (in shares)	20,657,240	20,764,354	11,602,049
Other comprehensive income:	'	'	'
Foreign currency translation adjustments	678	859	2
Comprehensive income	$19,055	$23,348	($692)

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Total
In Thousands, except Share data, unless otherwise specified
BALANCE at Dec. 31, 2010	$103	$15,290	$0	$13,507	$0	$28,900
BALANCE (in shares) at Dec. 31, 2010	10,256,364	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation related to stock options and restricted stock	0	7,774	0	'	0	7,774
Stock-based compensation - grants of common stock	20	13,843	0	0	0	13,863
Stock-based compensation - grant of common stock (in shares)	2,045,571	'	'	'	'	'
Exercise of stock options	28	382	0	0	0	410
Exercise of stock options (in shares)	2,783,303	'	'	'	'	'
Reverse merger acquisition	37	60,683	0	0	0	60,720
Reverse merger acquisition (in shares)	3,736,490	'	'	'	'	'
Purchase of Company Stock	0	0	-250	0	0	-250
Purchase of Company Stock (in shares)	0	'	'	'	'	16,056
Other comprehensive income	0	0	0	0	2	2
Net income (loss)	0	0	0	-694	0	-694
BALANCE at Dec. 31, 2011	188	97,972	-250	12,813	2	110,725
BALANCE (in shares) at Dec. 31, 2011	18,821,728	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Issuance of warrants to consultants for services	0	98	0	0	0	98
Stock-based compensation related to stock options and restricted stock	0	5,709	0	0	0	5,709
Stock-based compensation - grants of common stock	0	405	0	0	0	405
Stock-based compensation - grant of common stock (in shares)	30,000	'	'	'	'	'
Exercise of stock options	0	67	0	0	0	67
Exercise of stock options (in shares)	10,048	'	'	'	'	'
Stock options issued to consultants for services	0	83	0	0	0	83
Issuance of common stock, net	30	37,484	0	0	0	37,514
Issuance of common stock, net (in shares)	3,023,432	'	'	'	'	'
Repurchase and retirement of common stock	-9	-10,747	0	0	0	-10,756
Repurchase and retirement of common stock (in shares)	-842,961	'	'	'	'	'
Warrants exercised	1	133	0	0	0	134
Warrants exercised (in shares)	17,756	'	'	'	'	'
Retirement of treasury stock	0	-250	250	0	0	0
Retirement of treasury stock (in shares)	-16,056	'	'	'	'	'
Other comprehensive income	0	0	0	0	859	859
Net income (loss)	0	0	0	22,489	0	22,489
BALANCE at Dec. 31, 2012	210	130,954	0	35,302	861	167,327
BALANCE (in shares) at Dec. 31, 2012	21,043,947	'	'	'	'	21,043,947
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation related to stock options and restricted stock	0	4,892	0	0	0	4,892
Exercise of stock options	0	23	0	0	0	23
Exercise of stock options (in shares)	3,750	'	'	'	'	'
Purchase of Company Stock	'	'	'	'	'	-41,757
Stock options issued to consultants for services	0	93	0	0	0	93
Repurchase and retirement of common stock	-21	-31,008	0	0	0	-31,029
Repurchase and retirement of common stock (in shares)	-2,144,452	'	'	'	'	'
Other comprehensive income	0	0	0	0	678	678
Net income (loss)	0	0	0	18,377	0	18,377
BALANCE at Dec. 31, 2013	$189	$104,954	$0	$53,679	$1,539	$160,361
BALANCE (in shares) at Dec. 31, 2013	18,903,245	'	'	'	'	18,903,245

CONSOLIDATED_STATEMENTS_OF_CHA1

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)	12 Months Ended
	Dec. 31, 2011
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY [Abstract]	'
Purchase of Company stock (in shares)	16,056

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash Flows From Operating Activities:	'	'	'
Net income (loss)	$18,377	$22,489	($694)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation and amortization	6,119	5,611	590
Provision for doubtful accounts	5,958	4,629	2,595
Deferred income taxes	2,589	-2,330	-5,751
Stock-based compensation	4,985	6,197	21,637
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-13,944	-11,254	-6,135
Inventories	-4,967	-3,195	-993
Prepaid expenses and other assets	843	-8,583	-641
Accounts payable	4,658	1,787	-3,413
Accrued compensation and related expenses	733	-1,316	976
Other accrued liabilities (see Note 8)	-444	5,719	3,036
Other liabilities	233	68	76
Deferred revenues	130	5,243	2,176
Net cash provided by operating activities	25,270	25,065	13,459
Cash Flows From Investing Activities:	'	'	'
Purchases of property and equipment	-943	-573	-358
Lasers placed into service	-5,476	-3,221	15
Proceeds from (investments in) short-term deposit	3,887	-18,000	14,500
Increase in funds - employees retirement rights	-233	-69	-81
Acquisition of business, net of cash acquired	84	0	-18,729
Net cash used in investing activities	-2,681	-21,863	-4,653
Cash Flows From Financing Activities:	'	'	'
Repurchase of common stock	-31,029	-10,756	-250
Proceeds from issuance of common stock, net	0	37,514	0
Issuance of warrants	0	98	0
Proceeds from option exercises	23	67	410
Proceeds from warrant exercises	0	134	0
Proceeds from issuance of debt	10,000	0	0
Payments on notes payable	-623	-465	0
Repayment of long-term debt	-43	-2,000	0
Net cash (used in) provided by financing activities	-21,672	24,592	160
Effect of exchange rate changes on cash	123	5	2
Net increase in cash and cash equivalents	1,040	27,799	8,968
Cash and cash equivalents, beginning of year	44,348	16,549	7,581
Cash and cash equivalents, end of year	45,388	44,348	16,549
Supplemental information:	'	'	'
Cash paid for income taxes	7,233	12,976	6,373
Cash paid for interest	13	79	0
Fair value of assets, excluding cash, acquired in exchange for securities in a business combination	0	0	69,592
Fair value of liabilities assumed in exchange for securities in a business combination	0	0	11,035
Goodwill resulting from a business combination	$0	$0	$24,005

The_Company_and_Summary_of_Sig

The Company and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
The Company and Summary of Significant Accounting Policies [Abstract]	'
The Company and Summary of Significant Accounting Policies	'
	Note 1
	The Company and Summary of Significant Accounting Policies:
	The Company:
	Background
	PhotoMedex, Inc. (and its subsidiaries) (the “Company”) is a Global Skin Health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The Company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer) and photo damage.
	On December 13, 2011, the Company closed the merger with Radiancy, Inc. Immediately following the reverse merger, the pre-reverse merger shareholders of PhotoMedex, Inc. (“Pre-merged PhotoMedex”) collectively owned approximately 20% of the Company’s outstanding common stock, and the former Radiancy, Inc. stockholders owned approximately 80% of the Company’s outstanding common stock.
	The merger was accounted for as a reverse acquisition with Radiancy treated for accounting purposes as the acquirer. As such, the financial statements of Radiancy, Inc. were treated as the historical financial statements of the Company, with the results of Pre-merged PhotoMedex, Inc. being included from December 14, 2011 and thereafter. For periods prior to the closing of the reverse acquisition, therefore, our discussion below relates to the historical business and operations of Radiancy, Inc.
	As a result of the acquisition, the Company implemented a revised business plan focused on three key components – skilled direct sales force to target Physician and Professional Segments; expertise in global consumer marketing; and a full product life cycle model representing the ability to develop and commercialize innovative products from concept through regulatory, physician acceptance, and ultimately marketed directly to the consumer as dictated by normal product-life-cycle evolution. The Company reorganized its business into three operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers.
	On July 1, 2013, PhotoMedex’ wholly-owned subsidiary, Radiancy, Inc., completed the acquisition of 100% of the shares of LK Technology Importaçăo E Exportaçăo LTDA (“LK”), a privately-held distributor in Brazil based in Sao Paulo, and has begun to market and sell its no!no!® products in Brazil in the third quarter through its acquisition of LK. (See Note 2).
	Summary of Significant Accounting Policies:
	Accounting Principles
	The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company’s equity, net assets, results of operations or cash flows.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and the wholly and majority owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The financial statements include the results from the entities defined as Pre-merged PhotoMedex from December 14, 2011 (the day following the closing date of the reverse acquisition) forward. There are, therefore, no corresponding activities up to and including December 13, 2011.
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“US GAAP”) requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of December 31, 2013, the more significant estimates include (1) revenue recognition, including provision for sales return and valuation allowances of accounts receivable; (2) valuation allowance of deferred tax assets and uncertainty in tax positions; and (3) stock based compensation.
	Functional Currency
	The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the US dollar ("$" or "dollars"), except for the operations of Photo Therapeutics, Ltd. which are conducted in Great Britain Pounds (GBP) and LK Technologies which are conducted in Brazilian Real (BRL). Substantially all of the Group's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar. Thus, the functional (and reporting currency) of the Company and its subsidiaries (other than Photo Therapeutics, Ltd. and LK Technologies) is the dollar.
	Balances denominated in, or linked to, foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of comprehensive income, the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses.
	Assets and liabilities of foreign subsidiaries, whose functional currency is the local currency, are translated from its respective functional currency to U.S. dollars at the balance sheet date exchange rates. Income and expense items are translated at the average rates of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income. Deferred taxes are not provided on translation adjustments as the earnings of the subsidiaries are considered to be permanently reinvested.
	Fair Value Measurements
	The Company measures and discloses fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
		•	Level 1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
		•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
		•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
	The fair value of cash and cash equivalents and short term bank deposits are based on its demand value, which is equal to its carrying value. The estimated fair values of notes payable and long-term debt which are based on borrowing rates that are available to the Company for loans with similar terms, collateral and maturity approximate the carrying values. The fair value of the amounts funded in insurance policies in respect of employee liability for employee rights upon retirement is usually identical or close to their carrying value. Additionally, the carrying value of all other monetary assets and liabilities is estimated to be equal to their fair value due to the short-term nature of these instruments.
	Derivative financial instruments are measured at fair value, on a recurring basis. The fair value of derivatives generally reflects the estimated amounts that the Group would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency prices and the relevant interest rates. Such measurement is classified within Level 2. The fair value of contingent consideration in connection with the acquisition of LK (see Note 2) is based on management estimate of the entity prices of remaining inventories of LK at acquisition date (level 3 measurement).
	In addition to items that are measured at fair value on a recurring basis, there are also assets and liabilities that are measured at fair value on a nonrecurring basis. Assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets including goodwill. As such, we have determined that each of these fair value measurements reside within Level 3 of the fair value hierarchy.
	Cash and Cash Equivalents
	The Company invests its excess cash in highly liquid short-term investments. The Company considers short-term investments that are purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consisted of cash and money market accounts at December 31, 2013 and 2012.
	Short-term Deposits
	Short-term deposits are deposits with original maturities of more than three months but less than one year. Short-term deposits are presented at their costs including accrued interest.
	Accounts Receivable
	The majority of the Company’s accounts receivable are due from consumers, distributors (domestic and international), physicians and other entities in the medical field. Accounts receivable are most often due within 30 to 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company and available information about their credit risk, and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. The Company does not recognize interest accruing on accounts receivable past due.
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined to be purchased cost for raw materials and the production cost (materials, labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods. For the Company’s consumer and LHE products, cost is determined on the weighted-average method. For the pre-merged PhotoMedex’s products, cost is determined on the first-in, first-out method. Throughout the laser manufacturing process, the related production costs are recorded within inventory. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.
	The Company's equipment for the treatment of skin disorders (e.g. the XTRAC for psoriasis or vitiligo) will either (i) be placed in a physician's office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser, whether for sale or for placement, is accumulated in inventory.
	Reserves for slow moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trend.
	Property, Equipment and Depreciation
	Property and equipment are recorded at cost, net of accumulated depreciation. Excimer lasers-in-service are depreciated on a straight-line basis over the estimated useful life of five years. For other property and equipment, depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, primarily three to seven years for computer hardware and software, furniture and fixtures, and machinery and equipment. Leasehold improvements are amortized over the lesser of the useful lives or lease terms. Expenditures for major renewals and betterments to property and equipment are capitalized, while expenditures for maintenance and repairs are charged as an expense as incurred. Upon retirement or disposition, the applicable property amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of comprehensive income. Useful lives are determined based upon an estimate of either physical or economic obsolescence or both.
	Management evaluates the realizability of property and equipment based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. As of December 31, 2013, no such write-down was required (see Impairment of Long-Lived Assets below).
	Patent Costs and Licensed Technologies
	Costs incurred to obtain or defend patents and licensed technologies are capitalized and amortized over the shorter of the remaining estimated useful lives or eight to 12 years. Core and product technology was also recorded in connection with the reverse acquisition on December 13, 2011 and is being amortized on a straight-line basis over ten years for core technology and five years for product technology. (See Note 2, Reverse Acquisition and Note 5, Patent and Licensed Technologies).
	Management evaluates the recoverability of intangible assets based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. As of December 31, 2013, no such write-down was required. (See Impairment of Long-Lived Assets and Intangibles).
	Other Intangible Assets
	Other intangible assets were recorded in connection with the reverse acquisition on December 13, 2011. The assets which were determined to have definite useful lives are being amortized on a straight-line basis over ten years. Such assets primarily include customer relationships and trademarks. (See Note 2, Reverse Acquisition and Note 6, Goodwill and Other Intangible Assets).
	Management evaluates the recoverability of such other intangible assets based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. As of December 31, 2013 no such write-down was required. (See Impairment of Long-Lived Assets and Intangibles).
	Accounting for the Impairment of Goodwill
	The Company evaluates the carrying value of goodwill annually at the end of the calendar year and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. Goodwill impairment testing involves a two-step process. Step 1 compares the fair value of the Group’s reporting units to which goodwill was allocated to their carrying values. If the fair value of the reporting unit exceeds its carrying value, no further analysis is necessary. The reporting unit fair value is based upon consideration of various valuation methodologies, including guideline transaction multiples, multiples of current earnings, and projected future cash flows discounted at rates commensurate with the risk involved. If the carrying amount of the reporting unit exceeds its fair value, Step 2 must be completed to quantify the amount of impairment. Step 2 calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit, from the fair value of the reporting unit as determined in Step 1. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss, equal to the difference, is recognized. As of December 31, 2013, no impairment of goodwill has been recorded.
	Accrued Warranty Costs
	The Company offers a standard warranty on product sales generally for a one to two-year period. In the case of domestic sales of XTRAC lasers, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the expected cost of estimated future warranty claims on the date the product is sold. Total accrued warranty is included in other accrued liabilities on the balance sheet. The activity in the warranty accrual during the years ended December 31, 2013 and 2012 is summarized as follows:
			December 31,
			2013			2012
	Accrual at beginning of year		$	1,440		$	1,661
	Additions charged to warranty expense			1,206			1,497
	Expiring warranties			(410	)		(442	)
	Claims satisfied			(1,085	)		(1,276	)
	Total			1,151			1,440
	Less: current portion			(1,094	)		(1,274	)
	Long term accrued warranty		$	57		$	166
	For extended warranty on the consumer products, see Revenue Recognition below.
	Liability for Employee Rights Upon Retirement
Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company has recorded a severance pay liability for the amount that would be paid if all its Israeli employees were dismissed at the balance sheet date, on an undiscounted basis, in accordance with Israeli labor law. This liability is computed based upon the number of years of service multiplied by the latest monthly salary, since the employees are entitled to one month's salary for each year of employment, or a portion thereof. The amount of accrued severance pay as above represents the Company's severance pay liability in accordance with the labor agreement in force and based on salary components, which in the opinion of Management, create entitlement to severance pay.
The liability is partly funded by insurance policies, as the Company makes monthly deposits for such policies. The amounts funded are included under Funds in respect of employee rights upon retirement and other assets. The deposited funds include profits accumulated up to the balance sheet date. The deposited funds may be withdrawn upon the fulfillment of the obligation pursuant to Israeli severance pay laws or labor agreements. The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits.
Severance pay expenses amounted to approximately $201, $179 and $185 for the years ended December 31, 2013, 2012 and 2011, respectively.
Revenue Recognition
The Company recognizes revenues from the product sales when the following four criteria have been met: (i) the product has been delivered and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for estimated chargebacks, rebates, expected returns and cash discounts.
The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will insist upon FOB destination. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured.
For revenue arrangements with multiple deliverables within a single, contractually binding arrangements (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.
With respect to sales arrangements under which the buyer has a right to return the related product, revenue is recognized only if all the following conditions are met: the price is fixed or determinable at the date of sale; the buyer has paid, or is obligated to pay and the obligation is not contingent on resale of the product; the buyer's obligation would not be changed in the event of theft or physical destruction or damage of the product; the buyer has economic substance; the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and the amount of future returns can be reasonably estimated.
The Company provides a provision for product returns based on the experience with historical sales returns, in accordance with ASC Topic 605-15 with respect to sales of product when a right of return exists. Reported revenues are shown net of the returns provision. Such allowance for sales returns is included in Other Accrued Liabilities. (See Note 8).
Deferred revenue includes amounts received with respect to extended warranty maintenance, repairs and other billable services and amounts not yet recognized as revenues. Revenues with respect to such activities are deferred and recognized on a straight-line basis over the duration of the warranty period, the service period or when service is provided, as applicable to each service.
The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) sells its lasers through a distributor or directly to a physician or (ii) places its lasers in a physician’s office (at no charge to the physician) and generally charges the physician a fee for an agreed upon number of treatments. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.
When the Company places a laser in a physician’s office, it generally recognizes service revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.
The Company defers substantially all revenue from sales of treatment codes ordered by and performed to its customers within the last two weeks of the period in determining the amount of treatments performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.
Shipping and Handling Costs
Shipping and handling fees billed to customers are reflected as revenues while the related shipping and handling costs are included in selling and marketing expense. To date, shipping and handling costs have not been material.
Product Development Costs
Costs of research, new product development and product redesign are charged to expense as incurred.
Advertising Costs
Advertising costs are charged to expenses as incurred.
Advertising expenses amounted to approximately $71,992, $60,651 and $32,303 for the years ended December 31, 2013, 2012 and 2011, respectively.
Derivatives
The group applies the provisions of Accounting Standards Codification ("ASC") Topic 815, Derivatives and Hedging. In accordance with ASC Topic 815, all the derivative financial instruments are recognized as either financial assets or financial liabilities on the balance sheet at fair value. The accounting for changes in the fair value of a derivative financial instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For derivative financial instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.
From time to time the Company carries out transactions involving foreign exchange derivative financial instruments (mainly forward exchange contracts) which are designed to hedge the cash flows expected to be paid with respect to forecasted expenses of the Israeli subsidiary (Radiancy) denominated in Israeli local currency (NIS) which is different than its functional currency.
Such derivatives were not designated as hedging instruments, and accordingly they were recognized in the balance sheet at their fair value, with changes in the fair value carried to the Statement of Comprehensive Income and included in financing income (expenses), net.
At December 31, 2013, the balance of such derivative instruments amounted to approximately $255 in assets and approximately $699 were recognized as financing income in the Statement of Comprehensive Income during the year ended that date. At December 31, 2012, the balance of such derivative instruments amounted to approximately $402 in assets and approximately $289 were recognized as financing income in the Statement of Comprehensive Income during the year ended that date.
The nominal amounts of foreign currency derivatives as of December 31, 2013 consist of forward transactions for the exchange of $6,725 into NIS and $8,400 as of December 31, 2012.
Income Taxes
The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized.
The Company may incur an additional tax liability in the event of an intercompany dividend distribution, although it is the Company’s policy not to cause a distribution of dividends which would generate an additional tax liability to the Company in the foreseeable future. Upon the distribution of dividends from the tax-exempt income of an "Approved Enterprise" of an Israeli subsidiary (see Note 12), the amount distributed will be subject to the tax rate that would have been applicable had the Israeli subsidiary not been exempted from payment thereof. The Israeli subsidiary intends on permanently reinvesting the amounts of tax-exempt income and it does not intend on causing a distribution of such income as cash dividends. Therefore, no deferred income taxes have been provided in respect of such tax-exempt income. Taxes, which would apply in the event of disposal of investments in subsidiaries, have not been taken into account in computing the deferred taxes, as it is the Company's policy to hold these investments, not to dispose of them.
The Company accounts for uncertainty tax positions in accordance with an amendment to ASC Topic 740-10, Income Taxes (Accounting for Uncertainty in Income Taxes), which clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position can be recognized in the financial statements only if the position is "more-likely-than-not" to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard the likelihood that the tax position may be challenged. If an uncertain tax position meets the "more-likely-than-not" threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded.
In the year ended December 31, 2013, the Company determined that the liability for unrecognized tax benefits could suitably be extinguished by application of net operating loss carryforwards and carrybacks, with any residual impact arising as a liability in 2013 that has been duly provided for.
Concentration of credit risks
Financial instruments which subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, derivative (assets), accounts receivable and short-term bank deposits. The carrying amounts of these instruments approximate fair value due to their short-term nature. The Company deposits cash and cash equivalents and short term deposits in major financial institutions in the US, UK, Brazil and in Israel. The Company performs periodic evaluations of the relative credit standing of these institutions. The Company is of the opinion that the credit risk in respect of these balances is immaterial. In addition, the Company performs an ongoing credit evaluation and establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of customers (see also Accounts receivable above).
Most of the Company’s sales are generated in North America and Asia Pacific, to a large number of customers. Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts. Accordingly, the Company’s trade receivables do not represent a substantial concentration of credit risk.
Contingencies
The Company and its subsidiaries are involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Except for income tax contingencies, the Company records accruals for contingencies to the extent that the management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
Earnings (Loss) Per Share
The Company computes earnings (net loss) per share in accordance with ASC Topic. 260, Earnings per share. Basic earnings per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period, net of the weighted average number of treasury shares. Diluted earnings per common share are computed similar to basic earnings per share, except that the denominator is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period in which a net loss is reported or if their effect is anti-dilutive. The Company’s potential common shares consist of stock options, warrants and restricted stock awards issued under the Company’s stock incentive plans and their potential dilutive effect is considered using the treasury method.
Due to the reverse merger on December 13, 2011, the earnings per share for the period before the acquisition date presented in these financial statements were computed based on Radiancy’s historical weighted-average number of shares outstanding, multiplied by the exchange ratio that was established in the reverse merger. Therefore, unless otherwise noted, all share and per-share amounts for prior period to the acquisition date presented have been retroactively adjusted to give effect to the exchange ratio.
Basic and diluted earnings per common share were calculated using the following weighted average shares outstanding for the years ended December 31, 2013, 2012 and 2011:
		December 31,
		2013			2012			2011
Weighted average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding			20,454,970			20,355,520			11,602,049
Dilutive effect of stock options and warrants			202,270			408,834			-
Diluted number of common and common stock equivalent shares outstanding			20,657,240			20,764,354			11,602,049
Diluted earnings (loss) per share for each of the years ended December 31, 2013, 2012 and 2011 exclude the impact of common stock options, warrants and unvested restricted stock totaling 2,172,745, 1,920,442 and 1,791,788 shares, respectively, as the effect of their inclusion would be anti-dilutive.
Impairment of Long-Lived Assets and Intangibles
Long-lived assets, such as property and equipment, and definite-lived intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the fair value of the asset. If the carrying amount of an asset exceeds the fair value, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. As of December 31, 2013, no such impairment exists. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as discontinued operations are presented separately in the appropriate asset and liability sections of the balance sheet.
Share-Based Compensation
The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation – Stock Compensation. Under the fair value recognition provision, of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award that is ultimately expected to vest and is recognized as operating expense over the applicable vesting period of the stock award using the graded vesting method.
Treasury Stock and Repurchase of Common Stock
Shares held by the Company are presented as a reduction of equity, at their cost to the Company as treasury stock.
Adoption of New Accounting Standards
Effective January 1, 2013, the Company adopted Accounting Standard Update No. 2013-02, Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU Topic 220") This ASU requires entities to provide information about significant amounts reclassified out of accumulated other comprehensive income. The standard became effective, prospectively, for interim and annual periods beginning after December 15, 2012. The adoption of the standard did not impact the Company's consolidated results of operations and financial condition.
Effective January 1, 2013, the Company adopted Accounting Standard Update No. 2011-11, Balance Sheet – Disclosure about Offsetting Assets and Liabilities ("ASU 2011-11"). ASU 2011-11 enhances disclosures about financial instruments and derivative instruments that are either offset in accordance with the Accounting Standards Codification or are subject to an enforceable master netting arrangement or similar agreement. The amended guidance became effective, in a retrospective manner to all comparative periods presented, for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of the standard did not have a material impact on the Company's consolidated results of operations and financial condition.
Recently Issued Accounting Standards
In July 2013 the FASB has issued Accounting Standard Update 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force) ("ASU 2013-11").
The amendments in ASU 2013-11 state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be presented net of deferred tax assets.
ASU 2013-11 applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. For public companies the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted.
Management believes that the adoption of the amendments is not expected to have material impact on the Company's consolidated results of operations and financial condition.
In March 2013, the FASB issued Accounting Standards Update 2013-5, Foreign Currency Matters (Topic 830) Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity ("ASU 2013-5").
ASU 2013-5 clarifies that, when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business (other than a sale of in-substance real estate or conveyance of oil and gas mineral rights) within a foreign entity, the parent is required to apply the guidance in Subtopic 830-30 to release any related cumulative translation adjustment into net income. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. ASU 2013-5 also clarifies that if the business combination achieved in stages relates to a previously held equity method investment (step-acquisition) that is a foreign entity, the amount of accumulated other comprehensive income that is reclassified and included in the calculation of gain or loss shall include any foreign currency translation adjustment related to that previously held investment.
For public companies, the amendments in this Update will be effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The amendments should be applied prospectively to derecognition events occurring after the effective date. Prior periods should not be adjusted. Early adoption is permitted. If an entity elects to early adopt the amendments, it should apply them as of the beginning of the entity’s fiscal year of adoption. Management believes that the adoption of the standard is not expected to have a material impact on the Company's consolidated results of operations and financial condition.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2013
Acquisition [Abstract]	'
Acquisition	'
	Note 2
	Acquisition:
	On July 1, 2013, PhotoMedex’ wholly-owned subsidiary, Radiancy, Inc., completed the acquisition of 100% of the shares of LK Technology Importaçăo E Exportaçăo LTDA (“LK”), a privately-held distributor in Brazil.
	LK brings to PhotoMedex all required licenses, authorizations and permits to immediately begin its consumer business operating locally. LK was founded in 2003 and is based in Sao Paulo. LK has been operating for several years selling Radiancy’s professional line of products in Brazil. The local manager of LK will remain in his position.
	The total consideration was $181, consisting of $100 consideration and $81 (a contingent consideration component) liability for an estimated amount to be due for the profit to be earned on the remaining inventory at acquisition date. Such contingent amount is expected to be paid during the year 2014. Of the $100 consideration, $41 was a cash down payment and the balance of $59 is to be paid in 2014.
	The fair value of the assets acquired and liabilities assumed were based on management estimates. Based on the initial purchase price allocation, the following table summarizes the fair value amounts of the assets acquired and liabilities assumed at the date of the acquisition:
	Cash and cash equivalents	$	125
	Accounts receivable		1
	Inventories		20
	Prepaid expenses and other current assets		2
	Total assets acquired at fair value		148
	Accounts payable		(75	)
	Accrued compensation and related expenses		(2	)
	Other accrued liabilities		(11	)
	Total liabilities assumed		(88	)
	Net assets acquired	$	60
	The purchase price exceeded the fair value of the net assets acquired by $121, which was recorded as goodwill.
	The consolidated results of operations do not include any revenues or expenses related to the LK business on or prior to July 1, 2013, the consummation date of the acquisition. The amounts of revenue and earnings of LK since the acquisition date through December 31, 2013 included in the consolidated statement of comprehensive income were immaterial. Assuming the acquisition of LK had occurred on January 1, 2012, the impact on the Company’s results for the years ended December 31, 2013 and 2012 would have been immaterial. However this determination does not purport to be indicative of the results of operations which would have actually resulted had the acquisition occurred on January 1, 2012, nor to be indicative of future results of operations.
	Reverse Acquisition:
	On December 13, 2011, PhotoMedex closed the merger acquisition with Radiancy, Inc. in a transaction that was accounted for as a reverse acquisition, with Radiancy treated as the accounting acquirer. Radiancy was considered the accounting acquirer even though PhotoMedex was the issuer of common stock in the transaction, such that upon completion of the merger, the Company had 18,820,852 shares of common stock issued and outstanding, with the Pre-merged PhotoMedex, Inc. stockholders collectively owning approximately 20%, and the former Radiancy, Inc. stockholders owning approximately 80%, of the outstanding common stock of the Company.
	The consideration transferred was $82,562, and included $1,842 of assumed debt, for the Pre-merged PhotoMedex assets. This amount was determined based on the amount of equity interest (shares, options and warrants) that Radiancy would have had to issue to PhotoMedex shareholders in order to provide, as agreed upon in the merger document, a 75%/25% ownership ratio on a fully converted basis. Consistent with this formula all warrants and options were treated as equivalent, share for share, with outstanding common stock. The fair value of the consideration effectively transferred by Radiancy was based on the market price of Pre-merged PhotoMedex shares which was $15.60 per-share (closing price) on December 13, 2011, the day on which the reverse acquisition became effective. This consideration transferred also included $20 million in cash, which Pre-merged PhotoMedex, used to liquidate its convertible debt, prior to the acquisition. The $82,562 of consideration transferred was adjusted down during the measurement period of the reverse acquisition from the previously reported period by $1,353 to due to a change in valuation on unvested restricted stock of Pre Merged PhotoMedex as of December 13, 2011.
	The consolidated results of operations did not include any revenues or expenses related to the pre-merged PhotoMedex business on or prior to December 13, 2011, the consummation date of the reverse acquisition. The Company’s unaudited pro-forma results for the years ended December 31, 2011 summarize the combined results of the Radiancy and PhotoMedex in the following table, assuming the reverse acquisition had occurred on January 1, 2011 and after giving effect to the reverse acquisition adjustments, including amortization of the tangible and intangible assets that were acquired in the transaction:
		Year Ended
		31-Dec-11
		(unaudited)
	Net revenues	$	162,341
	Net income (loss)		(13,077	)
	Net income (loss) per share:
	Basic	$	(0.91	)
	Diluted	$	(0.91	)
	Shares used in calculating net income (loss) per share:
	Basic		14,445,184
	Diluted		14,445,184
	These unaudited pro-forma information have been prepared for comparative purposes only and do not purport to be indicative of the results of operations which would have actually resulted had the reverse acquisition occurred on January 1, 2011, nor to be indicative of future results of operations.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventories [Abstract]	'
Inventories	'
	Note 3
	Inventories:
		December 31,
		2013		2012
	Raw materials and work-in-process	$	12,631	$	9,012
	Finished goods		14,916		13,455
	Total inventories	$	27,547	$	22,467
	Work-in-process is immaterial given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment [Abstract]	'
Property and Equipment	'
	Note 4
	Property and Equipment:
		December 31,
		2013			2012
	Lasers-in-service	$	12,599		$	7,301
	Equipment, computer hardware and software		4,730			4,015
	Furniture and fixtures		705			617
	Leasehold improvements		534			396
			18,568			12,329
	Accumulated depreciation and amortization		(8,079	)		(5,570	)
	Total property and equipment, net	$	10,489		$	6,759
	Related depreciation and amortization expense was $2,875 in 2013, $2,367 in 2012 and $356 in 2011.

Patents_and_Licensed_Technolog

Patents and Licensed Technologies, net	12 Months Ended
	Dec. 31, 2013
Patents and Licensed Technologies, net [Abstract]	'
Patents and Licensed Technologies, net	'
	Note 5
	Patents and Licensed Technologies, net:
		December 31,
		2013			2012
	Gross Amount beginning of period	$	15,411		$	15,124
	Additions		171			181
	Translation differences		66			106
	Gross Amount end of period		15,648			15,411
	Accumulated amortization		(4,816	)		(2,738	)
	Net Book Value	$	10,832		$	12,673
	Related amortization expense was $2,043, $2,049 and $184 for the years ended December 31, 2013, 2012 and 2011, respectively. An amount of $13,500, included in Patents represents product and core technologies recorded as part of the purchase price allocation done in connection with the reverse acquisition of the Pre-merged PhotoMedex.
	Estimated amortization expense for amortizable patents and licensed technologies assets for the next five years is as follows:
	2014	$	2,052
	2015		2,045
	2016		2,040
	2017		905
	2018		905
	Thereafter		2,885
	Total	$	10,832

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Goodwill and Other Intangible Assets	'
	Note 6
	Goodwill and Other Intangible Assets:
	As part of the purchase price allocation for the reverse acquisition, the Company recorded goodwill in the amount of $24,005 and definite-lived intangibles in the amount of $12,000. Goodwill reflects the value or premium of the acquisition price in excess of the fair values assigned to specific tangible and intangible assets. Goodwill has an indefinite useful life and therefore is not amortized as an expense, but is reviewed annually for impairment of its fair value to the Company. The purchase price intrinsically recognizes the benefits of the broadened depth of the management team and the addition of a sizeable direct sales force creating greater access to the physician community with branded products and technologies. Furthermore, the purchase price paid by Radiancy, Inc, a private company includes, among other things, other benefits such as the intrinsic value of being a Nasdaq-listed issuer post merger and now having access to capital markets and stockholder liquidity.
	Balance at January 1, 2012	$	24,500
	Additions to goodwill		121
	Translation differences		309
	Balance at December 31, 2013	$	24,930
	The Company has no accumulated impairment losses as of December 31, 2013.
	The goodwill was allocated among the reportable segments as of December 31, 2013 in accordance with the provisions of ASC Topic 350-20 Intangibles-Goodwill and consisted of the following:
		31-Dec-13
	Consumer segment	$	20,850
	Physician Recurring segment		4,080
	Total goodwill	$	24,930
	Set forth below is a detailed listing of other definite-lived intangible assets:
		31-Dec-13									31-Dec-12
		Trademarks			Customer			Total			Trademarks			Customer			Total
					Relationships									Relationships
	Gross Amount beginning of period	$	5,744		$	6,372		$	12,116		$	5,700		$	6,300		$	12,000
	Translation differences		28			45			73			44			72			116
	Gross Amount end of period		5,772			6,417			12,189			5,744			6,372			12,116
	Accumulated amortization		(1,178	)		(1,310	)		(2,488	)		(598	)		(664	)		(1,262	)
	Net Book Value	$	4,594		$	5,107		$	9,701		$	5,146		$	5,708		$	10,854
	Related amortization expense was $1,200, $1,212 and $50 for the years ended December 31, 2013, 2012 and 2011. Customer Relationships embody the value to the Company of relationships that Pre-merged PhotoMedex had formed with its customers. Tradename includes the names and various other trademarks associated with Pre-merged PhotoMedex products (e.g. “XTRAC”, “Neova” “Omnilux” and “Lumiere”).
	Estimated amortization expense for the above amortizable intangible assets for the next five years is as follows:
	2014	$	1,200
	2015		1,200
	2016		1,200
	2017		1,200
	2018		1,200
	Thereafter		3,701
	Total	$	9,701

Accrued_Compensation_and_relat

Accrued Compensation and related expenses	12 Months Ended
	Dec. 31, 2013
Accrued Compensation and related expenses [Abstract]	'
Accrued Compensation and related expenses	'
	Note 7
	Accrued Compensation and related expenses:
		December 31,
		2013		2012
	Accrued payroll and related taxes	$	707	$	1,010
	Accrued vacation		290		262
	Accrued commissions and bonuses		2,233		1,222
	Total accrued compensation and related expense	$	3,230	$	2,494

Other_Accrued_Liabilities

Other Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Other Accrued Liabilities [Abstract]	'
Other Accrued Liabilities	'
	Note 8
	Other Accrued Liabilities:
			December 31,
			2013			2012
	Accrued warranty, current, see Note 1		$	1,094		$	1,274
	Accrued  taxes, including liability for unrecognized tax benefit, see Note 12			1,023			4,304
	Accrued sales return (1)			16,046			11,901
	Other accrued liabilities			3,869			4,620
	Total other accrued liabilities		$	22,032		$	22,099
	(1)	The activity in the sales returns liability account was as follows:
			December 31,
			2013			2012
	Balance at beginning of year		$	11,901		$	6,143
	Additions that reduce net sales			47,916			43,284
	Actual returns			(43,771	)		(37,526	)
	Balance at end of year		$	16,046		$	11,901

Shortterm_Debt

Short-term Debt	12 Months Ended
	Dec. 31, 2013
Short-term Debt: [Abstract]	'
Short-term Debt	'
	Note 9
	Short-term Debt:
	Term-Note Credit Facility
	In December 2013, the Company, through its subsidiary, Radiancy, Inc., entered into a term-note facility with JP Morgan Chase (“Chase”). The facility has maximum principal amount of $15 million and is for a term of one year. As of December 31, 2013, the Company had total borrowings of $10,000 under this facility. The stated interest rate for any draw under the credit facility was set as the greater of (i) prime rate, (ii) federal funds effective rate plus .5% or (iii) LIBOR plus 2.5%. Each draw has a repayment period of one year with principal due at maturity, although any draw may be paid early with penalty. On February 3, 2014, the Company repaid the entire balance of $10,000.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	Note 10
	Commitments and Contingencies:
	Leases
	The Company has entered into various non-cancelable operating lease agreements for real property and one minor operating lease for personal property. These arrangements expire at various dates through 2016. Rent expense was $1,002, $908 and $458 for the years ended December 31, 2013, 2012 and 2011, respectively. The future annual minimum payments under these leases are as follows:
	Year Ending December 31,
	2014	$	535
	2015		336
	2016		56
	Thereafter		-
	Total	$	927
	Litigation
	During the year ended December 31, 2013, Radiancy, Inc., a wholly-owned subsidiary of PhotoMedex, commenced legal action against Viatek Consumer Products Group, Inc., over Viatek’s Pearl and Samba hair removal products which Radiancy believes infringe the intellectual property covering its no!no! hair removal devices. The first suit, which was filed in the United States Federal Court, Southern District of New York, includes claims against Viatek for patent infringement, trademark and trade dress infringement, and false and misleading advertising. A second suit against Viatek was filed in Canada, where the Pearl is offered on that country’s The Shopping Channel, alleging trademark and trade dress infringement, and false and misleading advertising. Viatek’s response contains a variety of counterclaims and affirmative defenses against both Radiancy and its parent company PhotoMedex, including, among other counts, claims regarding the invalidity of Radiancy’s patents and antitrust allegations regarding Radiancy’s conduct.
	As of March 17, 2014, the case has proceeded into the discovery phase of the litigation. Radiancy, and PhotoMedex, have moved to dismiss PhotoMedex from the case, and to dismiss the counterclaims and affirmative defenses asserted by Viatek. Radiancy has also moved for sanctions against Viatek for failure to provide meaningful and timely responses to Radiancy’s discovery requests. No decision has yet been rendered on these motions. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case is still in the early stages of discovery to determine the validity of any claim or claims made by Viatek. Therefore, the Company has not recorded any reserve or contingent liability related to this particular legal matter. However, in the future, as the case progresses, the Company may be required to record a contingent liability or reserve for this matter.
	On December 20, 2013, PhotoMedex, Inc. was served with a putative class action lawsuit filed in the United States District Court for the Eastern District of Pennsylvania against the Company and its two top executives, Dolev Rafaeli, Chief Executive Officer, and Dennis M. McGrath, President and Chief Financial Officer. The suit, filed by Mr. Guy Ratz, a former employee of Radiancy (Israel) Ltd., a wholly-owned subsidiary of the Company, alleges various violations of the Federal securities laws between November 7, 2012 and November 14, 2013, including that the Company and its officers made false and misleading statements or failed to disclose material facts concerning the Company’s business. Two other shareholders filed suit through other firms; the Asbestos Workers Local 14 Pension Fund was appointed the lead plaintiff in this case. The complaint seeks certification of the putative class as well as an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys’ fees, expert witness fees and other costs. The Company and its officers intend to vigorously defend themselves against this lawsuit. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the cases have only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
	Four putative class-action lawsuits have been filed in connection with PhotoMedex’s proposed acquisition of LCA-Vision, Inc. Two of those suits have been filed in the Court of Chancery of the State of Delaware and two have been filed in the Court of Common Pleas of Hamilton County, Ohio. All cases assert claims against LCA-Vision, Inc., its chief executive officer and directors, PhotoMedex, and Gatorade Acquisition Corp., a wholly owned subsidiary of PhotoMedex. The complaints allege that the proposed acquisition undervalues LCA and deprives LCA’s shareholders of the opportunity to participate in LCA’s long-term financial prospects, that the “go shop” provisions of the Merger Agreement are intended to prevent LCA from soliciting or receiving competing offers, that LCA’s Board has breached its fiduciary duties and failed to maximize that company’s stockholder value, and that LCA, PhotoMedex, and Gatorade have aided and abetted the LCA defendants’ alleged breaches of duty. The complaints seek injunctive relief, unspecified damages, and other relief. As of March 17, 2014, defendants have not responded to the complaints in any of the actions. Defendants intend to vigorously defend themselves in the lawsuits. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the cases have only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
	The Company and certain of the Company’s subsidiaries are involved in certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which arise from time to time in the ordinary course of its business. Management believes, based on discussions with legal counsel, that these other litigation matters and claims will likely be resolved without a material effect on the Company’s consolidated financial position, results of operations or liquidity. However, litigation is inherently unpredictable, and excessive verdicts can result from litigation. Although the Company believes that it has substantial defenses in these matters, the Company may, in the future, incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in a particular period. As of December 31, 2013, management believes that there are not any contingencies that might cause a significant loss or that the occurrence is considered to be probable.
	Employment Agreements
	The Company has severance agreements with certain key executives and employees that create certain liabilities in the event of their termination of employment by the company without cause, or following a change in control of the Company. The aggregate commitment under these executive severance agreements, should all covered executives and employees be terminated other than for cause, was approximately $1,427 as of December 31, 2013, based on 2013 salary levels. Should all covered executives and certain key employees be terminated following a change in control of the Company, the aggregate commitment under these executive severance agreements at December 31, 2013 was approximately $1,174, based on 2013 salary levels.

Stockholders_Equity

Stockholders Equity	12 Months Ended
	Dec. 31, 2013
Stockholders Equity [Abstract]	'
Stockholders Equity	'
	Note 11
	Stockholders’ Equity:
	Preferred Stock
	The Company has authorized preferred stock consisting of 5,000,000 shares with a $.01 par value, which shall be designated as blank check preferred. The Board of Directors may authorize the issuance from time to time of one or more classes of preferred stock with one or more series within any class thereof, with such voting powers, full or limited, or without voting powers and with such designations, preferences and relative, participating, optional or special rights and qualifications, limitations or restrictions thereon as shall be set forth in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such preferred shares. At December 31, 2013 and 2012, no shares of preferred stock were outstanding.
	Common Stock
	On August 18, 2012, the Board of Directors approved a stock repurchase program up to a maximum to $25 million. In August 2013, the Board of Directors has authorized an additional $30 million share re-purchase program of its common shares in the open market over the next twelve months, at such times and prices as determined appropriate by the Company's management in collaboration with the Board of Directors. To date, the Company has repurchased 2,987,413 shares at an average price of $13.98 per share for a total of $41,757.
	On December 12, 2011, the stockholders voted to increase the number of authorized shares of common stock from 35,000,000 to 50,000,000 shares.
	On December 13, 2011, in conjunction with the reverse acquisition, the Company issued 15,084,370 shares of common stock to the shareholders of Radiancy, Inc. and also, 380,000 shares of restricted stock to two executives of per-merged PhotoMedex. These restricted shares vest over a three-year period.
	Common Stock Options
	Pre-Reverse Merger
	In 1999, Radiancy established a stock option plan (the "Plan") whereby 6,033,748 shares of the Company's common stock were reserved for issuance to eligible employees, directors and consultants. Stock options granted under the Plan generally vested ratably over a three-year period and expired 10 years from the date of the grant.
	As of the closing of the reverse acquisition, the Plan was discontinued and all outstanding option grants, not exercised, under the Plan were cancelled.
	Post-Reverse Merger
	Following the closing of the reverse acquisition, the previous Non-Employee Director Stock Option Plan of PhotoMedex (the acquired entity) was adopted by the group. This plan has authorized 120,000 shares; of which 7,000 shares had been issued or were reserved for issuance as awards of shares of common stock, and 17,077 shares were reserved for outstanding stock options. The directors, who were elected to our Board in connection with the reverse merger, each received a one-time stock award of 5,000 shares of the Company’s common stock in January 2012.
	In addition, following the closing of the reverse acquisition, the previous 2005 Equity Compensation Plan (“2005 Equity Plan”) of Pre-merged PhotoMedex (the acquired entity) was also adopted for use by the group. The 2005 Equity Plan has authorized 3,000,000 shares, of which 753,095 shares had been issued or were reserved for issuance as awards of shares of common stock, and 1,115,601 shares were reserved for outstanding options.
	A summary of option transactions for all of the Company’s stock options during the years ended December 31, 2013, 2012 and 2011:
			Number of Stock				Weighted
			Options				Average
							Exercise Price
	Outstanding at December 31, 2010			1,950,936			$	0.69
	Granted			1,476,279				0.04
	Exercised			(2,782,435	)			0.15
	Assumed in reverse merger			180,718				19.54
	Expired/cancelled			(644,780	)			1.32
	Outstanding at December 31, 2011			180,718				19.54
	Granted			739,000				15.87
	Exercised			(10,048	)			6.67
	Expired/cancelled			(11,129	)			20.25
	Outstanding at December 31, 2012			898,541				16.65
	Granted			259,625				16.59
	Exercised			(3,750	)			6.24
	Expired/cancelled			(21,738	)			31.36
	Outstanding at December 31, 2013			1,132,678			$	16.51
	Exercisable at December 31, 2013			320,053			$	17.35
	The outstanding and exercisable options at December 31, 2013, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:
	Options Range				Outstanding				Weighted Average				Weighted		Exercisable		Exercisable
	of Exercise				Number of				Remaining				Average		Number of		Weighted Avg.
	Prices				Shares				Contractual Life				Exercise Price		Shares		Exercise Price
									(years)
	$	0 - $15.00				691,831				8.33			$	13.92		145,706	$	12.45
	$	15.01 - $30.00				427,900				8.32			$	19.02		161,400	$	17.41
	$	30.01 - $45.00				2,169				4.02			$	39.41		2,169	$	39.41
	$	45.01 - $60.00				3,563				2.97			$	47.07		3,563	$	47.07
	$	60.01 - up				7,215				1.03			$	93.69		7,215	$	93.69
	Total					1,132,678				8.25			$	16.51		320,053	$	17.35
	The outstanding options will expire, as follows:
	Year Ending		Number of Shares				Weighted				Exercise Price
							Average
							Exercise Price
	2014			2,499			$	102.48			$	102.48
	2015			2,499			$	102.9			$	102.9
	2016			2,634			$	69.48			$	48.72 - $93.66
	2017			3,146			$	46.85			$	46.62 - $47.88
	2018 and later			1,121,900			$	15.91			$	5.70 - $20.00
				1,132,678			$	16.51			$	5.70 - $102.90
	As the share price as of December 31, 2013 was $12.95, the aggregate intrinsic value for options outstanding and exercisable was immaterial.
	The Company uses the Black-Scholes option-pricing model to estimate fair value of grants of stock options with the following weighted average assumptions:
			Year Ended December 31,
			2013				2012				2011
	Risk-free interest rate			1.3	%			1.2	%			N/A
	Volatility			85.25	%			85.53	%			N/A
	Expected dividend yield			0	%			0	%			N/A
	Expected life		5.5 years				5.5 years					N/A
Estimated forfeiture rate			0	%			0	%			N/A
Prior to the reverse acquisition, Radiancy calculated the expected volatility based on the historic volatility of comparable public companies which operate in the same industry sector. Currently, the Company calculates expected volatility for a share-based grant based on historic daily stock price observations of its common stock. For estimating the expected term of share-based grants made in the years ended December 31, 2013 and 2012, the Company has adopted the simplified method. The Company has used historical data to estimate expected employee behaviors related to option exercises and forfeitures and included these expected forfeitures as a part of the estimate of expense as of the grant date.
With respect to grants of options, the risk-free rate of interest is based on the U.S. zero-coupon US Government bond rates appropriate for the expected term of the grant or award.
On February 28, 2013, the Company granted an aggregate of 177,125 options to purchase common stock to a number of employees and consultants with a strike price of $15, which was higher than the quoted market value of our stock at the date of grants. The options vest over five years and expire ten years from the date of grant. Also on February 28, 2013, the Company granted an aggregate of 82,500 non-qualified options to purchase common stock to two executive employees with a strike price of $20, which was set to match the exercise price of the warrants issued in the reverse merger and was higher than the quoted market value of our stock at the date of grant. The aggregate fair value of the options granted was $2,590. The options vest over five years and expire ten years from the date of grant.
On January 26, 2012, the Company issued 30,000 shares of common stock to the six non-employee directors with an aggregate fair value of $405.
On March 18, 2012, the Company granted an aggregate of 509,000 options to purchase common stock to a number of employees and consultants with a strike price of $14, which was higher than the quoted market value of our stock at the date of grants. The options vest over five years and expire ten years from the date of grant. Also on March 18, 2012, the Company granted an aggregate of 230,000 non-qualified options to purchase common stock to two executive employees with a strike price of $20, which was set to match the exercise price of the warrants issued in the reverse merger and was higher than the quoted market value of our stock at the date of grant. The aggregate fair value of the options granted was $6,652. The options vest over five years and expire ten years from the date of grant.
On December 13, 2011, as part of the reverse merger, the Company issued 380,000 shares of restricted common stock to two executives of pre-merged PhotoMedex. These restricted shares have a purchase price of $0.01 per share and vest, and cease to be subject to the Company’s right of repurchase, over a three-year period. The Company determined the fair value of the awards to be the fair value of the Company’s common stock on the date of issuance less the value paid for the award, accordingly the fair value of this grant was $5,928.
As part of the reverse acquisition, the Company assumed 164,000 unvested restricted stock out of 200,000 shares of restricted stock awards that Pre-merged PhotoMedex were issued on March 30, 2011 to two of its senior executives. Based on the terms of the award between Pre-merged PhotoMedex and the grantees, the vesting of 36,000 of the restricted stock awards were accelerated as of December 13, 2011, the date of the reverse merger (the number of shares that could be vested without causing excise taxes under Sec. 4999 of the Internal Revenue Code to be imposed on the executive or the loss in any material respect of a deduction under Section 162(m) of the Internal Revenue Code).
This portion was accounted for as part of the consideration transferred, which was based on the amount of equity interest (shares and warrants) that Radiancy would have had to issue to PhotoMedex equity holders in order to provide the ownership ratio determined for the reverse acquisition.
The remaining 164,000 unvested restricted stock that were assumed by the company were accounted for at fair value as of the reverse acquisition date. Accordingly, the fair value of the awards will be recorded as compensation costs in the post-merger periods - at 3 equal annual installments over a 3-year period, on each anniversary of the closing of the merger, so long as the executive continues to be employed by the Company on each such date.
On June 30, 2011, the Board of Directors of Radiancy approved for its’ Chief Executive Officer (i) a stock award of 2,045,571 shares of the Company's common stock and (ii) a cash bonus as a "gross-ups" for compensation of tax payments (tax obligations, withholdings and other tax-related liabilities in connection with the stock award and cash award). The Company recorded stock-based compensation expense of $27.1 million (including the cash bonus in an amount of $12.3 million) in respect to this grant, for the year ended December 31, 2011.
In addition, on June 30, 2011, prior to the reverse acquisition, the Board of Directors of Radiancy approved a grant to certain of its directors, executives and employees of 732,292 stock options at an exercise price of $0.01, to purchase shares of the Company's common stock (each option is exercisable to 2.011 shares of common stock). The fair value estimation of the award was $13.62 per option. The contractual term of each option is 10 years from the date of grant. The vesting periods of the options are as follows:
	•	66,667 options vested upon the effective date of grant.
	•	49,470 options will vest on June 30, 2012
	•	616,155 options vest as: (i) 33% of the options on June 30, 2012; and (ii) as to the remaining options, 8 1/3% of the options on each of the end of the following eight consecutive quarters.
Upon consummation of the reverse merger, the Board of Directors accelerated the vesting periods so all outstanding options became fully vested and were available to exercise into shares of common stock. Options that were not exercised on that date were forfeited. Due to this accelerated vesting, 2,740,414 options were exercised into common shares.
Out of the total options exercised into shares of common stock during 2011, the Company shall have the right to repurchase 66,912 shares of common stock (the remaining balance as of December 31, 2013) at a price equal to the par value of such shares ($0.005 per share) in the event of either the resignation or the termination for cause according to the employment agreement of the employees with the Company or its subsidiary. The repurchase right will be subject to the same vesting periods as the option grants themselves. The Company accounted for the replacement of the options, with similar vesting terms, as a modification of an award and determined that the fair value of the replaced award equals the new award and therefore no incremental costs should be recorded. As a result, the stock based compensation of $50 will continue to be expensed over the original vesting period.
Total compensation expense was as $4,985, $6,197 and $34,001 for the years ended December 31, 2013, 2012 and 2011.
At December 31, 2013, there was $8,569 of total unrecognized compensation cost related to non-vested stock awards that is expected to be recognized over a weighted-average period of 2.75 years.
Common Stock Warrants
Following the closing of the reverse merger, the Company had warrants outstanding, a majority of which were issued in conjunction with the reverse merger on December 13, 2011. As a result of the reverse merger, Pre-merged PhotoMedex shareholders were issued warrants at a ratio of 0.305836 per each outstanding share held or a total of 1,026,435 warrants. The warrants have the following principal terms: (i) a warrant exercise price of $20 per share of common stock, (ii) an exercise period of three years, and (iii) the right of the Company to notify the holders of the warrants of an earlier expiration of the warrants, at any time following such time as the Company’s common stock will have had a closing trading price in excess of $30 per share for a period of 20 consecutive trading days, provided that such earlier expiration date shall not be earlier than that date which is 20 trading days following the delivery of such notification by the Company.
A summary of warrant transactions for the years ended December 31, 2013, 2012 and 2011 is as follows:
		Number of Warrants				Weighted
						Average
						Exercise Price
Outstanding at January 1, 2011			-			$	-
Issued			-				-
Assumed in reverse merger			1,067,240				19.98
Exercised			-				-
Expired/cancelled			-				-
Outstanding at December 31, 2011			1,067,240				19.98
Issued			25,000				20
Exercised			(17,756	)			7.5
Expired/cancelled			(11,216	)			47.04
Outstanding at December 31, 2012			1,063,268				19.91
Issued			-				-
Exercised			-				-
Expired/cancelled			(4,589	)			18.48
Outstanding at December 31, 2013			1,058,679			$	19.91
At December 31, 2013, all outstanding warrants were exercisable. As the share price as of December 31, 2013 was $12.95, the aggregate intrinsic value for warrants outstanding and exercisable was immaterial.
If not previously exercised, the outstanding warrants will expire as follows:
		Number of Warrants				Weighted
						Average
Year Ending December 31,						Exercise Price
2014			1,026,429			$	20
2015			32,250				17.19
			1,058,679			$	19.91
As all of the warrants were fully vested at the date of the consummation of the reverse merger, the fair value of the warrants at that date was included as part of the calculation of the consideration transferred, as the consideration was determined based on the equity interests Radiancy would have had to issue to the stockholders of Pre-merged PhotoMedex to provide them the same equity interests in the combined company.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	Note 12
	Income Taxes:
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.
	A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible. The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
	For the years ended December 31, 2013, 2012, and 2011, the following table summarizes the components of income before income taxes and the provision for income taxes:
		Year Ended December 31,
		2013			2012			2011
	Income (loss) before income tax:
	U.S.	$	7,698		$	3,152		$	( 16,309	)
	Israel		14,279			20,414			13,980
	Other Foreign		768			3,365			-
	Income before income taxes	$	22,745		$	26,931		$	( 2,329	)
	Income tax expense (benefit):
	United States -  Federal tax:
	Current	$	( 1,253	)	$	2,752		$	246
	Deferred		1,795			(1,572	)		(5,495	)
	United States - State tax:
	Current		180			315			-
	Deferred:		850			(2,074	)		(243	)
	Israel:
	Current		2,781			4,034			3,487
	Deferred		(237	)		(50	)		(17	)
	Other foreign:
	Current		54			1371			-
	Deferred:		200			(338	)		-
	Income tax expense (benefit)	$	4,370		$	4,438		$	(2,022	)
	For the years ended December 31, 2013, 2012 and 2011, the following table reconciles the federal statutory income tax rate to the effective income tax rate:
		Year Ended December 31,
		2013			2012			2011
	Federal Tax rate		35	%		35	%		35	%
	Federal tax expense (benefit) at 35%	$	7,961		$	9,426		$	( 815	)
	State and local income tax		958			286			(320	)
	Foreign rate differential		(2,656	)		(4,213	)		(3,654	)
	Increase in taxes from permanent differences in stock-based compensation		433			637			2,674
	US taxation of foreign earnings – Subpart F		367			403			-
	Increase (decrease) in uncertain tax positions		269			(2,325	)		-
	Return to provision and other adjustments		(1,964	)		-			-
	Impact of tax rate change on deferred taxes		(942	)		-			-
	Foreign tax credits		(341	)		-			-
	Change in valuation allowance		116			-			-
	Other		169			224			93
	Income tax expense (benefit)	$	4,370		$	4,438		$	( 2,022	)
	As of December 31, 2013, the Company had approximately $48 million of Federal net operating loss carryforwards in the United States. Approximately $18.4 million of the loss carryforward has been recognized in the deferred tax account without a valuation allowance. Such recognized carryforward has sufficient expected income and sufficient Section 382 limitation to be used in future years. The balance of the loss carryforward has been placed under a valuation allowance.
	After conversion to U.S. dollars, Photo Therapeutics Limited had approximately $11 million of net operating loss carryforwards. Additionally, an NOL of $0.3 million was recorded by the Company’s Brazilian subsidiary.
	As of December 31, 2013, the Company’s gross deferred tax asset pertaining to State net operating loss carryforwards approximated $1.971 million and expire generally through 2017 to 2033, depending on the particular State’s rules. A large portion of the State loss carryforwards have been placed under a valuation allowance, approximating $1.548 million.
	In addition, the Company has approximately $0.1 million of AMT credits. The Company is currently expected to utilize foreign tax credits on a current basis. None of the Federal research tax credit carryforwards from Pre-merged PhotoMedex are deemed utilizable due to the constraints of Section 382.
	The balance of the deferred tax asset at December 31, 2013 has a valuation allowance of $11,910, which offsets the gross valuation of Federal and State NOL carryforwards.
	The following table summarizes the components of deferred income tax assets and liabilities:
		December 31,
		2013			2012
	Loss carryforwards	$	21,092		$	20,122
	AMT credits		112			1,495
	Foreign tax credits		-			446
	Accrued employment expenses		1,256			718
	Amortization and write-offs		8,883			10,557
	Capitalized R&D costs		2,933			3,670
	Deferred revenues		84			301
	Depreciation		4,360			5,537
	Doubtful accounts		3,499			2,121
	Inventory reserves		822			-
	Other accruals and reserves		228			617
	Return allowances		5,660			4,118
	Translation adjustments		61			-
Gross deferred tax asset		48,990			49,702
Less: valuation allowance		(11,910	)		(10,075	)
Net deferred tax asset	$	37,080		$	39,627
Among current assets	$	13,041		$	19,441
Among other non-current assets		24,039			20,186
PhotoMedex files corporate income tax returns in the United States, both in the Federal jurisdiction and in various State jurisdictions. The Company is subject to Federal income tax examination for calendar years 2010 through 2013 and is also generally subject to various State income tax examinations for calendar years 2005 through 2013. Photo Therapeutics Limited files in the United Kingdom. Radiancy (Israel) Limited files in Israel. The Israeli subsidiary is subject to tax examination for calendar years 2010 through 2013.
The Israeli subsidiary is entitled to reduced tax rates regarding income that is subject to tax pursuant to the "approved enterprise" until end of year 2012 and "preferred enterprise" from year 2013. Other income is subject to the regular corporate income tax rate.
Change in Israel rates. Effective for tax periods beginning 1 January 2014, the standard corporate income tax rate was increased from 25% to 26.5% and preferred income tax rate (for preferred enterprise located in an area which is not development zone A) was increased to 16%.
Income derived from the approved enterprise was tax-exempt for the first two years. In the succeeding five to eight years (depending on the classification of the Company as a foreign-invested company) the income was taxed at a reduced rate. In the event of cash dividends from income which was tax-exempt as above, the Israeli subsidiary would have to pay 15% tax in respect of the amount distributed. The Israeli subsidiary intends to reinvest the amount of such tax-exempt income and not to distribute it as dividends.
The entitlement to the above benefits is contingent upon fulfillment of the conditions stipulated by the law, the regulations published thereunder (and the letters of approval for the specific investments in the approved enterprise) in the preferred enterprise. Management of the Israeli subsidiary believes that as of December 31, 2013 the subsidiary was in compliance with the above-mentioned conditions.
Change in U.K. rates.  In addition, effective for tax periods beginning on April 1, 2013, the United Kingdom tax rate was reduced from 24% to 23%. Further enacted decreases in the tax rate to 21% and 20% will take effect on April 1, 2014 and 2015 respectively. These changes in rate will affect the tax provision with regard to the tax attributes of Photo Therapeutics Limited, the United Kingdom subsidiary.
Unrecognized Tax Benefits. The Company is subject to income taxation in the U.S., Israel, the U.K., and Brazil. Unrecognized tax benefits reflect the difference between positions taken or expected to be taken on income tax returns and the amounts recognized in the financial statements. Resolution of the related tax positions through negotiations with the relevant tax authorities or through litigation could take years to complete. It is difficult predict the timing of resolution for tax positions since such timing is not entirely within the control of the Company. It is reasonably possible that the total amount of unrecognized tax benefits could both increase and decrease in the next 12 months, with no material impact on earnings.
The Company and its subsidiaries file income tax returns in the United States, Israel and the United Kingdom.
In 2012, Management conducted an analysis of the facts and law surrounding the then existing income tax uncertainties, and found that such liability as may have arisen was of a much lesser magnitude and is able to be extinguished by loss carryforwards and carrybacks,
Reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
Balance at January 1, 2011	$	2,700
Additions / Settlements during 2011		-
Balance December 31, 2011		2,700
Additions/ Settlements due 2012		(2,325	)
Balance at December 31, 2012		375
Additions / Settlements due 2013		269
Balance at December 31, 2013	$	644

Significant_Customer_Concentra

Significant Customer Concentration	12 Months Ended
	Dec. 31, 2013
Significant Customer Concentration [Abstract]	'
Significant Customer Concentration	'
	Note 13
	Significant Customer Concentration:
	No customer was more than 10% of total company revenues for the years ended December 31, 2013 and 2012. There was one customer, Ya-Man, that was 20% of total company revenues for the year ended December 31, 2011.

Business_Segment_and_Geographi

Business Segment and Geographic Data	12 Months Ended
	Dec. 31, 2013
Business Segment and Geographic Data [Abstract]	'
Business Segment and Geographic Data	'
	Note 14
	Business Segment and Geographic Data:
	Effective December 13, 2011, the Company reorganized its business into three operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers, as follows: The Consumer segment derives its revenues from the design, development, manufacturing and selling of long-term hair reduction and acne consumer products. The Physician Recurring segment derives its revenues from the XTRAC procedures performed by dermatologists, the sales of skincare products, the sales of surgical disposables and accessories to hospitals and surgery centers and on the repair, maintenance and replacement parts on our various products. The Professional segment generates revenues from the sale of equipment, such as lasers, medical and esthetic light and heat based products and LED products. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.
	Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Unallocated assets include cash and cash equivalents, prepaid expenses and deposits.
	The following tables reflect results of operations from our business segments for the periods indicated below:
		Year ended December 31, 2013
		CONSUMER			PHYSICIAN			PROFESSIONAL			TOTAL
					RECURRING
	Revenues	$	188,259		$	28,548		$	7,857		$	224,664
	Costs of revenues		26,794			13,022			5,219			45,035
	Gross profit		161,465			15,526			2,638			179,629
	Gross profit %		85.8	%		54.4	%		33.6	%		80	%
	Allocated operating expenses:
	Engineering and product development		1,100			1,371			835			3,306
	Selling and marketing expenses		112,898			12,681			1,949			127,528
	Unallocated operating expenses		-			-			-			26,750
			113,998			14,052			2,784			157,584
	Income (loss) from operations		47,467			1,474			(146	)		22,045
	Interest  and other financing income (expense), net		-			-			-			702
	Net income (loss) before taxes	$	47,467		$	1,474		$	( 146	)	$	22,747
		Year ended December 31, 2012
		CONSUMER			PHYSICIAN			PROFESSIONAL			TOTAL
					RECURRING
	Revenues	$	188,425		$	21,284		$	10,942		$	220,651
	Costs of revenues		28,965			11,512			6,165			46,642
	Gross profit		159,460			9,772			4,777			174,009
	Gross profit %		84.6	%		45.9	%		43.7	%		78.9	%
	Allocated operating expenses:
	Engineering and product development		876			1,201			837			2,914
	Selling and marketing expenses		102,736			10,203			3,548			116,487
	Unallocated operating expenses		-			-			-			27,330
			103,612			11,404			4,385			146,731
	Income (loss) from operations		55,848			(1,632	)		392			27,278
	Interest  and other financing income (expense), net		-			-			-			(351	)
	Net income (loss) before taxes	$	55,848		$	( 1,632	)	$	392		$	26,927
		Year ended December 31, 2011
		CONSUMER			PHYSICIAN			PROFESSIONAL			TOTAL
					RECURRING
	Revenues	$	125,581		$	829		$	5,672		$	132,082
	Costs of revenues		23,309			456			2,531			26,296
	Gross profit		102,272			373			3,141			105,786
	Gross profit %		81.4	%		45	%		55.4	%		80.1	%
	Allocated operating expenses:
	Engineering and product development		837			27			193			1,057
	Selling and marketing expenses		59,424			319			2,442			62,185
	Unallocated operating expenses		-			-			-			45,192
			60,261			346			2,635			108,434
	Income (loss) from operations		42,011			27			506			(2,648	)
	Interest and other financing income (expense), net		-			-			-			(68	)
	Net income (loss) before taxes	$	42,011		$	27		$	506		$	(2,716	)
	For the years ended December 31, 2013, 2012 and 2011, net revenues by geographic area were as follows:
		Year Ended December 31,
		2013			2012			2011
	North America 1	$	174,850		$	163,973		$	91,821
	Asia Pacific 2		19,081			28,031			28,213
	Europe (including Israel)		27,849			25,521			9,994
	South America		2,884			3,126			2,054
		$	224,664		$	220,651		$	132,082
	1 United States	$	112,635		$	135,950		$	75,341
	1 Canada	$	62,215		$	28,023		$	16,480
	2  Japan	$	11,556		$	21,134		$	25,924
	For the years ended December 31, 2013, 2012 and 2011, long-lived assets by geographic area were as follows:
		Year Ended December 31,
	2013			2012			2011
North America	$	9,119		$	5,772		$	4,496
Asia Pacific		-			-			-
Europe (including Israel)		1,370			987			828
South America		-			-			-
	$	10,489		$	6,759		$	5,324

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited) [Abstract]	'
Quarterly Financial Data (Unaudited)	'
	Note 15
	Quarterly Financial Data (Unaudited):
		For the Quarter Ended
	2013	Mar. 31		Jun. 30			Sep. 30		Dec. 31
	Revenues	$	57,216	$	58,065		$	45,893	$	63,490
	Gross profit		45,350		46,675			36,827		50,777
	Net income		7,212		7,094			886		3,185
	Net income per share:
	Basic	$	0.35	$	0.34		$	0.04	$	0.16
	Diluted	$	0.34	$	0.34		$	0.04	$	0.16
	Shares used in computing net income per share:
	Basic		20,678,023		20,573,048			19,982,967		19,400,341
	Diluted		21,147,583		21,033,349			20,441,262		19,602,611
	2012	Mar. 31		Jun. 30			Sep. 30		Dec. 31
	Revenues	$	50,273	$	58,906		$	56,681	$	54,791
	Gross profit		39,039		46,551			45,400		43,019
	Net income		4,857		4,213			7,525		5,894
	Net income per share:
	Basic	$	0.26	$	0.2		$	0.35	$	0.28
	Diluted	$	0.26	$	0.2		$	0.35	$	0.27
	Shares used in computing net income per share:
	Basic		18,339,977		20,547,244			21,205,675		20,947,985
	Diluted		18,876,163		21,034,814			21,752,845		21,356,819
	2011	Mar. 31		Jun. 30			Sep. 30		Dec. 31
	Revenues	$	34,741	$	33,847		$	34,745	$	28,749
	Gross profit		28,519		28,157			26,603		22,507
	Net income (loss)		8,085		(10,045	)		4,249		(2,983	)
	Net income (loss) per share:
	Basic	$	0.79	$	(0.98	)	$	0.34	$	(0.22	)
	Diluted	$	0.68	$	(0.98	)	$	0.32	$	(0.22	)
	Shares used in computing net income (loss) per share:
	Basic		10,256,364		10,256,364			12,341,723		13,509,866
	Diluted		11,819,587		10,256,364			13,182,818		13,509,866

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Valuation and Qualifying Accounts	'
	Note 16
	Valuation and Qualifying Accounts:
					Additions Charged to
			Balance at		Cost and		Other		Deductions (2)			Balance at End
			Beginning		Expenses		Accounts (1)					of Period
	Description		of Period
	For The Year Ended December 31, 2013:
	Reserve for Doubtful Accounts		$	6,917	$	5,958	$	-	$	(2,141	)	$	10,734
	Reserve for Sales Returns		$	11,901	$	47,914	$	-	$	( 43,770	)	$	16,045
	For The Year Ended December 31, 2012:
	Reserve for Doubtful Accounts		$	3,196	$	4,629	$	-	$	( 908	)	$	6,917
	Reserve for Sales Returns		$	6,143	$	43,284	$	-	$	( 37,526	)	$	11,901
	For The Year Ended December 31, 2011:
	Reserve for Doubtful Accounts		$	1,824	$	2,595	$	70	$	(1,293	)	$	3,196
	Reserve for Sales Returns		$	3,406	$	26,610	$	-	$	( 23,873	)	$	6,143
	(1)	Represents additions due to the reverse merger on December 13, 2011.
	(2)	Represents write-offs of specific accounts receivable and actual returns.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 17
	Subsequent Events:
	On February 13, 2014, the Company, LCA-Vision Inc. (NasdaqGS: LCAV), a Delaware corporation (“LCA”), and Gatorade Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) under which the Company has agreed to acquire LCA. Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions therein, Merger Sub will be merged with and into LCA (the “Merger”), with LCA surviving as a wholly-owned subsidiary of the Company.
	At the effective time of the merger, each outstanding share of LCA common stock (other than dissenting shares, treasury shares, any shares owned by the Company and its subsidiaries, and shares owned by a subsidiary of LCA) will be cancelled, and the shareholders will receive $5.37 in cash, without interest. Immediately prior to the effective time of the Merger, each outstanding option to acquire common stock granted under any LCA equity incentive plan, whether vested or exercisable, that is outstanding will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of $5.37 over the per share exercise price of the option multiplied by (ii) the total number of shares of common stock subject to the option. Also immediately prior to the effective time of the Merger, each outstanding share of restricted stock unit award or other right to receive common stock granted under any LCA equity incentive plan, whether vested or exercisable, will be cancelled and converted into the right to receive $5.37 per share in cash, without interest. The $5.37 per ownership interest price represents a premium of 34% over the closing price of LCA common stock on February 12, 2014, or an approximate purchase price of $106.4 million for all LCA stock and equity instruments described above.
	The Company intends to fund this transaction through a new $85 million senior secured credit facility including a $10 million revolving credit facility and a $75 million four-year term loan, as well as through existing cash balances. However, the Merger is not conditioned upon the Company receiving such financing.
	The Merger Agreement contains customary representations, warranties and covenants by both the Company and LCA. The parties’ obligations to complete the Merger are contingent upon customary closing conditions, including the approval of the Merger and the adoption of the Merger Agreement by the holders of a majority of the outstanding shares of LCA common stock, and the expiration or termination of the applicable Hart-Scott-Rodino Antitrust Improvements Act waiting period. The boards of directors of both the Comapny and LCA have voted unanimously in favor of the transaction, which is expected to close in the second quarter of 2014.
	The Merger Agreement also contains a 30-day “go-shop” period, which runs from the date of the Merger Agreement through March 15, 2014 (the “Go-Shop Period”). During this period, LCA may initiate or solicit alternative proposals from third parties for the sale of LCA (“Alternative Proposals”). However, starting on March 16, 2014, LCA will become subject to customary “window-shop” restrictions on its ability to solicit and act with regard to Alternative Proposals, although LCA may continue to engage in negotiations with third parties that submitted Alternative Proposals during the Go-Shop Period or respond to an unsolicited Alternative Proposal under certain circumstances.
	The Merger Agreement includes defined termination rights for both the Company and LCA. Under certain specified circumstances, LCA is entitled to terminate the Merger Agreement to accept an Alternative Proposal. The Merger Agreement includes a termination fee of approximately $3.2 million, plus up to $1 million in expenses, payable under certain specified circumstances, including if LCA terminates the Merger Agreement in order to enter into a definitive agreement with an alternative buyer, if the Company terminates the Merger Agreement for LCA’s board of directors' failure to reaffirm its recommendation of the transaction with the Company, or as a result of LCA’s uncured breach of representations, warranties and covenants in the Merger Agreement.

The_Company_and_Summary_of_Sig1

The Company and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
The Company and Summary of Significant Accounting Policies [Abstract]	'
Accounting Principles	'
	Accounting Principles
	The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company’s equity, net assets, results of operations or cash flows.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and the wholly and majority owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The financial statements include the results from the entities defined as Pre-merged PhotoMedex from December 14, 2011 (the day following the closing date of the reverse acquisition) forward. There are, therefore, no corresponding activities up to and including December 13, 2011.
Use of Estimates	'
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“US GAAP”) requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of December 31, 2013, the more significant estimates include (1) revenue recognition, including provision for sales return and valuation allowances of accounts receivable; (2) valuation allowance of deferred tax assets and uncertainty in tax positions; and (3) stock based compensation.
Functional Currency	'
	Functional Currency
	The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the US dollar ("$" or "dollars"), except for the operations of Photo Therapeutics, Ltd. which are conducted in Great Britain Pounds (GBP) and LK Technologies which are conducted in Brazilian Real (BRL). Substantially all of the Group's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar. Thus, the functional (and reporting currency) of the Company and its subsidiaries (other than Photo Therapeutics, Ltd. and LK Technologies) is the dollar.
	Balances denominated in, or linked to, foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of comprehensive income, the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses.
	Assets and liabilities of foreign subsidiaries, whose functional currency is the local currency, are translated from its respective functional currency to U.S. dollars at the balance sheet date exchange rates. Income and expense items are translated at the average rates of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income. Deferred taxes are not provided on translation adjustments as the earnings of the subsidiaries are considered to be permanently reinvested.
Fair Value Measurements	'
	Fair Value Measurements
	The Company measures and discloses fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
		•	Level 1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
		•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
		•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
	The fair value of cash and cash equivalents and short term bank deposits are based on its demand value, which is equal to its carrying value. The estimated fair values of notes payable and long-term debt which are based on borrowing rates that are available to the Company for loans with similar terms, collateral and maturity approximate the carrying values. The fair value of the amounts funded in insurance policies in respect of employee liability for employee rights upon retirement is usually identical or close to their carrying value. Additionally, the carrying value of all other monetary assets and liabilities is estimated to be equal to their fair value due to the short-term nature of these instruments.
	Derivative financial instruments are measured at fair value, on a recurring basis. The fair value of derivatives generally reflects the estimated amounts that the Group would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency prices and the relevant interest rates. Such measurement is classified within Level 2. The fair value of contingent consideration in connection with the acquisition of LK (see Note 2) is based on management estimate of the entity prices of remaining inventories of LK at acquisition date (level 3 measurement).
	In addition to items that are measured at fair value on a recurring basis, there are also assets and liabilities that are measured at fair value on a nonrecurring basis. Assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets including goodwill. As such, we have determined that each of these fair value measurements reside within Level 3 of the fair value hierarchy.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company invests its excess cash in highly liquid short-term investments. The Company considers short-term investments that are purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consisted of cash and money market accounts at December 31, 2013 and 2012.
Short-term Deposits	'
	Short-term Deposits
	Short-term deposits are deposits with original maturities of more than three months but less than one year. Short-term deposits are presented at their costs including accrued interest.
Accounts Receivable	'
	Accounts Receivable
	The majority of the Company’s accounts receivable are due from consumers, distributors (domestic and international), physicians and other entities in the medical field. Accounts receivable are most often due within 30 to 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company and available information about their credit risk, and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. The Company does not recognize interest accruing on accounts receivable past due.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined to be purchased cost for raw materials and the production cost (materials, labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods. For the Company’s consumer and LHE products, cost is determined on the weighted-average method. For the pre-merged PhotoMedex’s products, cost is determined on the first-in, first-out method. Throughout the laser manufacturing process, the related production costs are recorded within inventory. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.
	The Company's equipment for the treatment of skin disorders (e.g. the XTRAC for psoriasis or vitiligo) will either (i) be placed in a physician's office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser, whether for sale or for placement, is accumulated in inventory.
	Reserves for slow moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trend.
Property, Equipment and Depreciation	'
	Property, Equipment and Depreciation
	Property and equipment are recorded at cost, net of accumulated depreciation. Excimer lasers-in-service are depreciated on a straight-line basis over the estimated useful life of five years. For other property and equipment, depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, primarily three to seven years for computer hardware and software, furniture and fixtures, and machinery and equipment. Leasehold improvements are amortized over the lesser of the useful lives or lease terms. Expenditures for major renewals and betterments to property and equipment are capitalized, while expenditures for maintenance and repairs are charged as an expense as incurred. Upon retirement or disposition, the applicable property amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of comprehensive income. Useful lives are determined based upon an estimate of either physical or economic obsolescence or both.
	Management evaluates the realizability of property and equipment based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. As of December 31, 2013, no such write-down was required (see Impairment of Long-Lived Assets below).
Patent Costs and Licensed Technologies	'
	Patent Costs and Licensed Technologies
	Costs incurred to obtain or defend patents and licensed technologies are capitalized and amortized over the shorter of the remaining estimated useful lives or eight to 12 years. Core and product technology was also recorded in connection with the reverse acquisition on December 13, 2011 and is being amortized on a straight-line basis over ten years for core technology and five years for product technology. (See Note 2, Reverse Acquisition and Note 5, Patent and Licensed Technologies).
	Management evaluates the recoverability of intangible assets based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. As of December 31, 2013, no such write-down was required. (See Impairment of Long-Lived Assets and Intangibles).
Other Intangible Assets	'
	Other Intangible Assets
	Other intangible assets were recorded in connection with the reverse acquisition on December 13, 2011. The assets which were determined to have definite useful lives are being amortized on a straight-line basis over ten years. Such assets primarily include customer relationships and trademarks. (See Note 2, Reverse Acquisition and Note 6, Goodwill and Other Intangible Assets).
	Management evaluates the recoverability of such other intangible assets based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. As of December 31, 2013 no such write-down was required. (See Impairment of Long-Lived Assets and Intangibles).
Accounting for the Impairment of Goodwill	'
	Accounting for the Impairment of Goodwill
	The Company evaluates the carrying value of goodwill annually at the end of the calendar year and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. Goodwill impairment testing involves a two-step process. Step 1 compares the fair value of the Group’s reporting units to which goodwill was allocated to their carrying values. If the fair value of the reporting unit exceeds its carrying value, no further analysis is necessary. The reporting unit fair value is based upon consideration of various valuation methodologies, including guideline transaction multiples, multiples of current earnings, and projected future cash flows discounted at rates commensurate with the risk involved. If the carrying amount of the reporting unit exceeds its fair value, Step 2 must be completed to quantify the amount of impairment. Step 2 calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit, from the fair value of the reporting unit as determined in Step 1. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss, equal to the difference, is recognized. As of December 31, 2013, no impairment of goodwill has been recorded.
Accrued Warranty Costs	'
	Accrued Warranty Costs
	The Company offers a standard warranty on product sales generally for a one to two-year period. In the case of domestic sales of XTRAC lasers, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the expected cost of estimated future warranty claims on the date the product is sold. Total accrued warranty is included in other accrued liabilities on the balance sheet. The activity in the warranty accrual during the years ended December 31, 2013 and 2012 is summarized as follows:
			December 31,
			2013			2012
	Accrual at beginning of year		$	1,440		$	1,661
	Additions charged to warranty expense			1,206			1,497
	Expiring warranties			(410	)		(442	)
	Claims satisfied			(1,085	)		(1,276	)
	Total			1,151			1,440
	Less: current portion			(1,094	)		(1,274	)
	Long term accrued warranty		$	57		$	166
	For extended warranty on the consumer products, see Revenue Recognition below.
Liability for Employee Rights Upon Retirement	'
	Liability for Employee Rights Upon Retirement
	Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company has recorded a severance pay liability for the amount that would be paid if all its Israeli employees were dismissed at the balance sheet date, on an undiscounted basis, in accordance with Israeli labor law. This liability is computed based upon the number of years of service multiplied by the latest monthly salary, since the employees are entitled to one month's salary for each year of employment, or a portion thereof. The amount of accrued severance pay as above represents the Company's severance pay liability in accordance with the labor agreement in force and based on salary components, which in the opinion of Management, create entitlement to severance pay.
	The liability is partly funded by insurance policies, as the Company makes monthly deposits for such policies. The amounts funded are included under Funds in respect of employee rights upon retirement and other assets. The deposited funds include profits accumulated up to the balance sheet date. The deposited funds may be withdrawn upon the fulfillment of the obligation pursuant to Israeli severance pay laws or labor agreements. The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits.
	Severance pay expenses amounted to approximately $201, $179 and $185 for the years ended December 31, 2013, 2012 and 2011, respectively.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenues from the product sales when the following four criteria have been met: (i) the product has been delivered and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for estimated chargebacks, rebates, expected returns and cash discounts.
	The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will insist upon FOB destination. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured.
	For revenue arrangements with multiple deliverables within a single, contractually binding arrangements (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.
	With respect to sales arrangements under which the buyer has a right to return the related product, revenue is recognized only if all the following conditions are met: the price is fixed or determinable at the date of sale; the buyer has paid, or is obligated to pay and the obligation is not contingent on resale of the product; the buyer's obligation would not be changed in the event of theft or physical destruction or damage of the product; the buyer has economic substance; the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and the amount of future returns can be reasonably estimated.
	The Company provides a provision for product returns based on the experience with historical sales returns, in accordance with ASC Topic 605-15 with respect to sales of product when a right of return exists. Reported revenues are shown net of the returns provision. Such allowance for sales returns is included in Other Accrued Liabilities. (See Note 8).
	Deferred revenue includes amounts received with respect to extended warranty maintenance, repairs and other billable services and amounts not yet recognized as revenues. Revenues with respect to such activities are deferred and recognized on a straight-line basis over the duration of the warranty period, the service period or when service is provided, as applicable to each service.
	The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) sells its lasers through a distributor or directly to a physician or (ii) places its lasers in a physician’s office (at no charge to the physician) and generally charges the physician a fee for an agreed upon number of treatments. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.
	When the Company places a laser in a physician’s office, it generally recognizes service revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.
	The Company defers substantially all revenue from sales of treatment codes ordered by and performed to its customers within the last two weeks of the period in determining the amount of treatments performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	Shipping and handling fees billed to customers are reflected as revenues while the related shipping and handling costs are included in selling and marketing expense. To date, shipping and handling costs have not been material.
Product Development Costs	'
	Product Development Costs
	Costs of research, new product development and product redesign are charged to expense as incurred.
Advertising Costs	'
	Advertising Costs
	Advertising costs are charged to expenses as incurred.
	Advertising expenses amounted to approximately $71,992, $60,651 and $32,303 for the years ended December 31, 2013, 2012 and 2011, respectively.
Derivatives	'
	Derivatives
	The group applies the provisions of Accounting Standards Codification ("ASC") Topic 815, Derivatives and Hedging. In accordance with ASC Topic 815, all the derivative financial instruments are recognized as either financial assets or financial liabilities on the balance sheet at fair value. The accounting for changes in the fair value of a derivative financial instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For derivative financial instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.
	From time to time the Company carries out transactions involving foreign exchange derivative financial instruments (mainly forward exchange contracts) which are designed to hedge the cash flows expected to be paid with respect to forecasted expenses of the Israeli subsidiary (Radiancy) denominated in Israeli local currency (NIS) which is different than its functional currency.
	Such derivatives were not designated as hedging instruments, and accordingly they were recognized in the balance sheet at their fair value, with changes in the fair value carried to the Statement of Comprehensive Income and included in financing income (expenses), net.
	At December 31, 2013, the balance of such derivative instruments amounted to approximately $255 in assets and approximately $699 were recognized as financing income in the Statement of Comprehensive Income during the year ended that date. At December 31, 2012, the balance of such derivative instruments amounted to approximately $402 in assets and approximately $289 were recognized as financing income in the Statement of Comprehensive Income during the year ended that date.
	The nominal amounts of foreign currency derivatives as of December 31, 2013 consist of forward transactions for the exchange of $6,725 into NIS and $8,400 as of December 31, 2012.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized.
	The Company may incur an additional tax liability in the event of an intercompany dividend distribution, although it is the Company’s policy not to cause a distribution of dividends which would generate an additional tax liability to the Company in the foreseeable future. Upon the distribution of dividends from the tax-exempt income of an "Approved Enterprise" of an Israeli subsidiary (see Note 12), the amount distributed will be subject to the tax rate that would have been applicable had the Israeli subsidiary not been exempted from payment thereof. The Israeli subsidiary intends on permanently reinvesting the amounts of tax-exempt income and it does not intend on causing a distribution of such income as cash dividends. Therefore, no deferred income taxes have been provided in respect of such tax-exempt income. Taxes, which would apply in the event of disposal of investments in subsidiaries, have not been taken into account in computing the deferred taxes, as it is the Company's policy to hold these investments, not to dispose of them.
	The Company accounts for uncertainty tax positions in accordance with an amendment to ASC Topic 740-10, Income Taxes (Accounting for Uncertainty in Income Taxes), which clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position can be recognized in the financial statements only if the position is "more-likely-than-not" to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard the likelihood that the tax position may be challenged. If an uncertain tax position meets the "more-likely-than-not" threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded.
	In the year ended December 31, 2013, the Company determined that the liability for unrecognized tax benefits could suitably be extinguished by application of net operating loss carryforwards and carrybacks, with any residual impact arising as a liability in 2013 that has been duly provided for.
Concentration of credit risks	'
	Concentration of credit risks
	Financial instruments which subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, derivative (assets), accounts receivable and short-term bank deposits. The carrying amounts of these instruments approximate fair value due to their short-term nature. The Company deposits cash and cash equivalents and short term deposits in major financial institutions in the US, UK, Brazil and in Israel. The Company performs periodic evaluations of the relative credit standing of these institutions. The Company is of the opinion that the credit risk in respect of these balances is immaterial. In addition, the Company performs an ongoing credit evaluation and establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of customers (see also Accounts receivable above).
	Most of the Company’s sales are generated in North America and Asia Pacific, to a large number of customers. Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts. Accordingly, the Company’s trade receivables do not represent a substantial concentration of credit risk.
Contingencies	'
	Contingencies
	The Company and its subsidiaries are involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Except for income tax contingencies, the Company records accruals for contingencies to the extent that the management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
Earnings (Loss) Per Share	'
	Earnings (Loss) Per Share
	The Company computes earnings (net loss) per share in accordance with ASC Topic. 260, Earnings per share. Basic earnings per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period, net of the weighted average number of treasury shares. Diluted earnings per common share are computed similar to basic earnings per share, except that the denominator is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period in which a net loss is reported or if their effect is anti-dilutive. The Company’s potential common shares consist of stock options, warrants and restricted stock awards issued under the Company’s stock incentive plans and their potential dilutive effect is considered using the treasury method.
	Due to the reverse merger on December 13, 2011, the earnings per share for the period before the acquisition date presented in these financial statements were computed based on Radiancy’s historical weighted-average number of shares outstanding, multiplied by the exchange ratio that was established in the reverse merger. Therefore, unless otherwise noted, all share and per-share amounts for prior period to the acquisition date presented have been retroactively adjusted to give effect to the exchange ratio.
	Basic and diluted earnings per common share were calculated using the following weighted average shares outstanding for the years ended December 31, 2013, 2012 and 2011:
			December 31,
			2013			2012			2011
	Weighted average number of common and common equivalent shares outstanding:
	Basic number of common shares outstanding			20,454,970			20,355,520			11,602,049
	Dilutive effect of stock options and warrants			202,270			408,834			-
	Diluted number of common and common stock equivalent shares outstanding			20,657,240			20,764,354			11,602,049
	Diluted earnings (loss) per share for each of the years ended December 31, 2013, 2012 and 2011 exclude the impact of common stock options, warrants and unvested restricted stock totaling 2,172,745, 1,920,442 and 1,791,788 shares, respectively, as the effect of their inclusion would be anti-dilutive.
Impairment of Long-Lived Assets and Intangibles	'
	Impairment of Long-Lived Assets and Intangibles
	Long-lived assets, such as property and equipment, and definite-lived intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the fair value of the asset. If the carrying amount of an asset exceeds the fair value, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. As of December 31, 2013, no such impairment exists. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as discontinued operations are presented separately in the appropriate asset and liability sections of the balance sheet.
Share-Based Compensation	'
	Share-Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation – Stock Compensation. Under the fair value recognition provision, of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award that is ultimately expected to vest and is recognized as operating expense over the applicable vesting period of the stock award using the graded vesting method.
Treasury Stock and Repurchase of Common Stock	'
	Treasury Stock and Repurchase of Common Stock
	Shares held by the Company are presented as a reduction of equity, at their cost to the Company as treasury stock.
Adoption of New Accounting Standards	'
	Adoption of New Accounting Standards
	Effective January 1, 2013, the Company adopted Accounting Standard Update No. 2013-02, Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU Topic 220") This ASU requires entities to provide information about significant amounts reclassified out of accumulated other comprehensive income. The standard became effective, prospectively, for interim and annual periods beginning after December 15, 2012. The adoption of the standard did not impact the Company's consolidated results of operations and financial condition.
	Effective January 1, 2013, the Company adopted Accounting Standard Update No. 2011-11, Balance Sheet – Disclosure about Offsetting Assets and Liabilities ("ASU 2011-11"). ASU 2011-11 enhances disclosures about financial instruments and derivative instruments that are either offset in accordance with the Accounting Standards Codification or are subject to an enforceable master netting arrangement or similar agreement. The amended guidance became effective, in a retrospective manner to all comparative periods presented, for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of the standard did not have a material impact on the Company's consolidated results of operations and financial condition.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	In July 2013 the FASB has issued Accounting Standard Update 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force) ("ASU 2013-11").
	The amendments in ASU 2013-11 state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be presented net of deferred tax assets.
	ASU 2013-11 applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. For public companies the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted.
	Management believes that the adoption of the amendments is not expected to have material impact on the Company's consolidated results of operations and financial condition.
	In March 2013, the FASB issued Accounting Standards Update 2013-5, Foreign Currency Matters (Topic 830) Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity ("ASU 2013-5").
	ASU 2013-5 clarifies that, when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business (other than a sale of in-substance real estate or conveyance of oil and gas mineral rights) within a foreign entity, the parent is required to apply the guidance in Subtopic 830-30 to release any related cumulative translation adjustment into net income. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. ASU 2013-5 also clarifies that if the business combination achieved in stages relates to a previously held equity method investment (step-acquisition) that is a foreign entity, the amount of accumulated other comprehensive income that is reclassified and included in the calculation of gain or loss shall include any foreign currency translation adjustment related to that previously held investment.
	For public companies, the amendments in this Update will be effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The amendments should be applied prospectively to derecognition events occurring after the effective date. Prior periods should not be adjusted. Early adoption is permitted. If an entity elects to early adopt the amendments, it should apply them as of the beginning of the entity’s fiscal year of adoption. Management believes that the adoption of the standard is not expected to have a material impact on the Company's consolidated results of operations and financial condition.

The_Company_and_Summary_of_Sig2

The Company and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
The Company and Summary of Significant Accounting Policies [Abstract]	'
Activity in the warranty accrual	'
	The activity in the warranty accrual during the years ended December 31, 2013 and 2012 is summarized as follows:
		December 31,
		2013			2012
	Accrual at beginning of year	$	1,440		$	1,661
	Additions charged to warranty expense		1,206			1,497
	Expiring warranties		(410	)		(442	)
	Claims satisfied		(1,085	)		(1,276	)
	Total		1,151			1,440
	Less: current portion		(1,094	)		(1,274	)
	Long term accrued warranty	$	57		$	166
Calculation of basic and diluted earnings per common share using weighted average shares outstanding	'
	Basic and diluted earnings per common share were calculated using the following weighted average shares outstanding for the years ended December 31, 2013, 2012 and 2011:
		December 31,
		2013			2012			2011
	Weighted average number of common and common equivalent shares outstanding:
	Basic number of common shares outstanding		20,454,970			20,355,520			11,602,049
	Dilutive effect of stock options and warrants		202,270			408,834			-
	Diluted number of common and common stock equivalent shares outstanding		20,657,240			20,764,354			11,602,049

Acquisition_Tables

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2013
Acquisition [Abstract]	'
Schedule of Purchase Price Allocation	'
	Based on the initial purchase price allocation, the following table summarizes the fair value amounts of the assets acquired and liabilities assumed at the date of the acquisition:
	Cash and cash equivalents	$	125
	Accounts receivable		1
	Inventories		20
	Prepaid expenses and other current assets		2
	Total assets acquired at fair value		148
	Accounts payable		(75	)
	Accrued compensation and related expenses		(2	)
	Other accrued liabilities		(11	)
	Total liabilities assumed		(88	)
	Net assets acquired	$	60
Unaudited pro-forma results	'
	The Company’s unaudited pro-forma results for the years ended December 31, 2011 summarize the combined results of the Radiancy and PhotoMedex in the following table, assuming the reverse acquisition had occurred on January 1, 2011 and after giving effect to the reverse acquisition adjustments, including amortization of the tangible and intangible assets that were acquired in the transaction:
		Year Ended
		31-Dec-11
		(unaudited)
	Net revenues	$	162,341
	Net income (loss)		(13,077	)
	Net income (loss) per share:
	Basic	$	(0.91	)
	Diluted	$	(0.91	)
	Shares used in calculating net income (loss) per share:
	Basic		14,445,184
	Diluted		14,445,184

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventories [Abstract]	'
Schedule of Inventories	'
	Inventories:
		December 31,
		2013		2012
	Raw materials and work-in-process	$	12,631	$	9,012
	Finished goods		14,916		13,455
	Total inventories	$	27,547	$	22,467

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment [Abstract]	'
Schedule property and equipment	'
	Property and Equipment:
		December 31,
		2013			2012
	Lasers-in-service	$	12,599		$	7,301
	Equipment, computer hardware and software		4,730			4,015
	Furniture and fixtures		705			617
	Leasehold improvements		534			396
			18,568			12,329
	Accumulated depreciation and amortization		(8,079	)		(5,570	)
	Total property and equipment, net	$	10,489		$	6,759

Patents_and_Licensed_Technolog1

Patents and Licensed Technologies, net (Tables)	12 Months Ended
	Dec. 31, 2013
Patents and Licensed Technologies, net [Abstract]	'
Schedule of patents and licensed technologies	'
	Patents and Licensed Technologies, net:
		December 31,
		2013			2012
	Gross Amount beginning of period	$	15,411		$	15,124
	Additions		171			181
	Translation differences		66			106
	Gross Amount end of period		15,648			15,411
	Accumulated amortization		(4,816	)		(2,738	)
	Net Book Value	$	10,832		$	12,673
Amortization expense for amortizable patents and licensed technologies	'
	Estimated amortization expense for amortizable patents and licensed technologies assets for the next five years is as follows:
	2014	$	2,052
	2015		2,045
	2016		2,040
	2017		905
	2018		905
	Thereafter		2,885
	Total	$	10,832

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Schedule of goodwill acquired	'
	The purchase price intrinsically recognizes the benefits of the broadened depth of the management team and the addition of a sizeable direct sales force creating greater access to the physician community with branded products and technologies. Furthermore, the purchase price paid by Radiancy, Inc, a private company includes, among other things, other benefits such as the intrinsic value of being a Nasdaq-listed issuer post merger and now having access to capital markets and stockholder liquidity.
	Balance at January 1, 2012	$	24,500
	Additions to goodwill		121
	Translation differences		309
	Balance at December 31, 2013	$	24,930
Schedule of goodwill allocated to reportable segments	'
	The goodwill was allocated among the reportable segments as of December 31, 2013 in accordance with the provisions of ASC Topic 350-20 Intangibles-Goodwill and consisted of the following:
		31-Dec-13
	Consumer segment	$	20,850
	Physician Recurring segment		4,080
	Total goodwill	$	24,930
Schedule of other definite-lived intangible assets	'
	Set forth below is a detailed listing of other definite-lived intangible assets:
		31-Dec-13									31-Dec-12
		Trademarks			Customer			Total			Trademarks			Customer			Total
					Relationships									Relationships
	Gross Amount beginning of period	$	5,744		$	6,372		$	12,116		$	5,700		$	6,300		$	12,000
	Translation differences		28			45			73			44			72			116
	Gross Amount end of period		5,772			6,417			12,189			5,744			6,372			12,116
	Accumulated amortization		(1,178	)		(1,310	)		(2,488	)		(598	)		(664	)		(1,262	)
	Net Book Value	$	4,594		$	5,107		$	9,701		$	5,146		$	5,708		$	10,854
Schedule of estimated amortization expense for amortizable intangible assets	'
	Estimated amortization expense for the above amortizable intangible assets for the next five years is as follows:
	2014	$	1,200
	2015		1,200
	2016		1,200
	2017		1,200
	2018		1,200
	Thereafter		3,701
	Total	$	9,701

Accrued_Compensation_and_relat1

Accrued Compensation and related expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Compensation and related expenses [Abstract]	'
Schedule of accrued compensation and related expenses	'
	Accrued Compensation and related expenses:
		December 31,
		2013		2012
	Accrued payroll and related taxes	$	707	$	1,010
	Accrued vacation		290		262
	Accrued commissions and bonuses		2,233		1,222
	Total accrued compensation and related expense	$	3,230	$	2,494

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Other Accrued Liabilities [Abstract]	'
Schedule of other accrued liabilities	'
	Other Accrued Liabilities:
			December 31,
			2013			2012
	Accrued warranty, current, see Note 1		$	1,094		$	1,274
	Accrued  taxes, including liability for unrecognized tax benefit, see Note 12			1,023			4,304
	Accrued sales return (1)			16,046			11,901
	Other accrued liabilities			3,869			4,620
	Total other accrued liabilities		$	22,032		$	22,099
	(1)	The activity in the sales returns liability account was as follows:
			December 31,
			2013			2012
	Balance at beginning of year		$	11,901		$	6,143
	Additions that reduce net sales			47,916			43,284
	Actual returns			(43,771	)		(37,526	)
	Balance at end of year		$	16,046		$	11,901

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Schedule of future annual lease payments under leases	'
	The future annual minimum payments under these leases are as follows:
	Year Ending December 31,
	2014	$	535
	2015		336
	2016		56
	Thereafter		-
	Total	$	927

Stockholders_Equity_Tables

Stockholders Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders Equity [Abstract]	'
Stock option activity under share-based compensation plans	'
	A summary of option transactions for all of the Company’s stock options during the years ended December 31, 2013, 2012 and 2011:
			Number of Stock				Weighted
			Options				Average
							Exercise Price
	Outstanding at December 31, 2010			1,950,936			$	0.69
	Granted			1,476,279				0.04
	Exercised			(2,782,435	)			0.15
	Assumed in reverse merger			180,718				19.54
	Expired/cancelled			(644,780	)			1.32
	Outstanding at December 31, 2011			180,718				19.54
	Granted			739,000				15.87
	Exercised			(10,048	)			6.67
	Expired/cancelled			(11,129	)			20.25
	Outstanding at December 31, 2012			898,541				16.65
	Granted			259,625				16.59
	Exercised			(3,750	)			6.24
	Expired/cancelled			(21,738	)			31.36
	Outstanding at December 31, 2013			1,132,678			$	16.51
	Exercisable at December 31, 2013			320,053			$	17.35
Schedule of outstanding and exercisable options	'
	The outstanding and exercisable options at December 31, 2013, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:
	Options Range				Outstanding				Weighted Average				Weighted		Exercisable		Exercisable
	of Exercise				Number of				Remaining				Average		Number of		Weighted Avg.
	Prices				Shares				Contractual Life				Exercise Price		Shares		Exercise Price
									(years)
	$	0 - $15.00				691,831				8.33			$	13.92		145,706	$	12.45
	$	15.01 - $30.00				427,900				8.32			$	19.02		161,400	$	17.41
	$	30.01 - $45.00				2,169				4.02			$	39.41		2,169	$	39.41
	$	45.01 - $60.00				3,563				2.97			$	47.07		3,563	$	47.07
	$	60.01 - up				7,215				1.03			$	93.69		7,215	$	93.69
	Total					1,132,678				8.25			$	16.51		320,053	$	17.35
Schedule of outstanding options	'
	The outstanding options will expire, as follows:
	Year Ending		Number of Shares				Weighted				Exercise Price
							Average
							Exercise Price
	2014			2,499			$	102.48			$	102.48
	2015			2,499			$	102.9			$	102.9
	2016			2,634			$	69.48			$	48.72 - $93.66
	2017			3,146			$	46.85			$	46.62 - $47.88
	2018 and later			1,121,900			$	15.91			$	5.70 - $20.00
				1,132,678			$	16.51			$	5.70 - $102.90
Weighted average assumptions used to estimate fair value of stock options	'
	The Company uses the Black-Scholes option-pricing model to estimate fair value of grants of stock options with the following weighted average assumptions:
			Year Ended December 31,
			2013				2012				2011
	Risk-free interest rate			1.3	%			1.2	%			N/A
	Volatility			85.25	%			85.53	%			N/A
	Expected dividend yield			0	%			0	%			N/A
	Expected life		5.5 years				5.5 years					N/A
	Estimated forfeiture rate			0	%			0	%			N/A
Summary of warrant transactions	'
	A summary of warrant transactions for the years ended December 31, 2013, 2012 and 2011 is as follows:
			Number of Warrants				Weighted
							Average
							Exercise Price
	Outstanding at January 1, 2011			-			$	-
	Issued			-				-
	Assumed in reverse merger			1,067,240				19.98
	Exercised			-				-
	Expired/cancelled			-				-
	Outstanding at December 31, 2011			1,067,240				19.98
	Issued			25,000				20
	Exercised			(17,756	)			7.5
	Expired/cancelled			(11,216	)			47.04
	Outstanding at December 31, 2012			1,063,268				19.91
	Issued			-				-
	Exercised			-				-
	Expired/cancelled			(4,589	)			18.48
	Outstanding at December 31, 2013			1,058,679			$	19.91
Summary of warrant transactions expiration period	'
	If not previously exercised, the outstanding warrants will expire as follows:
			Number of Warrants				Weighted
							Average
	Year Ending December 31,						Exercise Price
	2014			1,026,429			$	20
	2015			32,250				17.19
				1,058,679			$	19.91

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income tax expense (benefit), net of valuation allowance	'
	For the years ended December 31, 2013, 2012, and 2011, the following table summarizes the components of income before income taxes and the provision for income taxes:
		Year Ended December 31,
		2013			2012			2011
	Income (loss) before income tax:
	U.S.	$	7,698		$	3,152		$	( 16,309	)
	Israel		14,279			20,414			13,980
	Other Foreign		768			3,365			-
	Income before income taxes	$	22,745		$	26,931		$	( 2,329	)
	Income tax expense (benefit):
	United States -  Federal tax:
	Current	$	( 1,253	)	$	2,752		$	246
	Deferred		1,795			(1,572	)		(5,495	)
	United States - State tax:
	Current		180			315			-
	Deferred:		850			(2,074	)		(243	)
	Israel:
	Current		2,781			4,034			3,487
	Deferred		(237	)		(50	)		(17	)
	Other foreign:
	Current		54			1371			-
	Deferred:		200			(338	)		-
	Income tax expense (benefit)	$	4,370		$	4,438		$	(2,022	)
Reconciliation of the effective tax rate	'
	For the years ended December 31, 2013, 2012 and 2011, the following table reconciles the federal statutory income tax rate to the effective income tax rate:
		Year Ended December 31,
		2013			2012			2011
	Federal Tax rate		35	%		35	%		35	%
	Federal tax expense (benefit) at 35%	$	7,961		$	9,426		$	( 815	)
	State and local income tax		958			286			(320	)
	Foreign rate differential		(2,656	)		(4,213	)		(3,654	)
	Increase in taxes from permanent differences in stock-based compensation		433			637			2,674
	US taxation of foreign earnings – Subpart F		367			403			-
	Increase (decrease) in uncertain tax positions		269			(2,325	)		-
	Return to provision and other adjustments		(1,964	)		-			-
	Impact of tax rate change on deferred taxes		(942	)		-			-
	Foreign tax credits		(341	)		-			-
	Change in valuation allowance		116			-			-
	Other		169			224			93
	Income tax expense (benefit)	$	4,370		$	4,438		$	( 2,022	)
Deferred tax assets (liabilities)	'
	The following table summarizes the components of deferred income tax assets and liabilities:
		December 31,
		2013			2012
	Loss carryforwards	$	21,092		$	20,122
	AMT credits		112			1,495
	Foreign tax credits		-			446
	Accrued employment expenses		1,256			718
	Amortization and write-offs		8,883			10,557
	Capitalized R&D costs		2,933			3,670
	Deferred revenues		84			301
	Depreciation		4,360			5,537
	Doubtful accounts		3,499			2,121
	Inventory reserves		822			-
	Other accruals and reserves		228			617
	Return allowances		5,660			4,118
	Translation adjustments		61			-
	Gross deferred tax asset		48,990			49,702
	Less: valuation allowance		(11,910	)		(10,075	)
	Net deferred tax asset	$	37,080		$	39,627
	Among current assets	$	13,041		$	19,441
	Among other non-current assets		24,039			20,186
Reconciliation of the beginning and ending amount of unrecognized tax benefits	'
	Reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
	Balance at January 1, 2011	$	2,700
	Additions / Settlements during 2011		-
	Balance December 31, 2011		2,700
	Additions/ Settlements due 2012		(2,325	)
	Balance at December 31, 2012		375
	Additions / Settlements due 2013		269
	Balance at December 31, 2013	$	644

Business_Segment_and_Geographi1

Business Segment and Geographic Data (Tables)	12 Months Ended
	Dec. 31, 2013
Business Segment and Geographic Data [Abstract]	'
Results of operations from business segments	'
	The following tables reflect results of operations from our business segments for the periods indicated below:
		Year ended December 31, 2013
		CONSUMER			PHYSICIAN			PROFESSIONAL			TOTAL
					RECURRING
	Revenues	$	188,259		$	28,548		$	7,857		$	224,664
	Costs of revenues		26,794			13,022			5,219			45,035
	Gross profit		161,465			15,526			2,638			179,629
	Gross profit %		85.8	%		54.4	%		33.6	%		80	%
	Allocated operating expenses:
	Engineering and product development		1,100			1,371			835			3,306
	Selling and marketing expenses		112,898			12,681			1,949			127,528
	Unallocated operating expenses		-			-			-			26,750
			113,998			14,052			2,784			157,584
	Income (loss) from operations		47,467			1,474			(146	)		22,045
	Interest  and other financing income (expense), net		-			-			-			702
	Net income (loss) before taxes	$	47,467		$	1,474		$	( 146	)	$	22,747
		Year ended December 31, 2012
		CONSUMER			PHYSICIAN			PROFESSIONAL			TOTAL
					RECURRING
	Revenues	$	188,425		$	21,284		$	10,942		$	220,651
	Costs of revenues		28,965			11,512			6,165			46,642
	Gross profit		159,460			9,772			4,777			174,009
	Gross profit %		84.6	%		45.9	%		43.7	%		78.9	%
	Allocated operating expenses:
	Engineering and product development		876			1,201			837			2,914
	Selling and marketing expenses		102,736			10,203			3,548			116,487
	Unallocated operating expenses		-			-			-			27,330
			103,612			11,404			4,385			146,731
	Income (loss) from operations		55,848			(1,632	)		392			27,278
	Interest  and other financing income (expense), net		-			-			-			(351	)
	Net income (loss) before taxes	$	55,848		$	( 1,632	)	$	392		$	26,927
		Year ended December 31, 2011
		CONSUMER			PHYSICIAN			PROFESSIONAL			TOTAL
					RECURRING
	Revenues	$	125,581		$	829		$	5,672		$	132,082
	Costs of revenues		23,309			456			2,531			26,296
	Gross profit		102,272			373			3,141			105,786
	Gross profit %		81.4	%		45	%		55.4	%		80.1	%
	Allocated operating expenses:
	Engineering and product development		837			27			193			1,057
	Selling and marketing expenses		59,424			319			2,442			62,185
	Unallocated operating expenses		-			-			-			45,192
			60,261			346			2,635			108,434
	Income (loss) from operations		42,011			27			506			(2,648	)
	Interest and other financing income (expense), net		-			-			-			(68	)
	Net income (loss) before taxes	$	42,011		$	27		$	506		$	(2,716	)
Net revenues and long-lived assets by geographical area	'
	For the years ended December 31, 2013, 2012 and 2011, net revenues by geographic area were as follows:
		Year Ended December 31,
		2013			2012			2011
	North America 1	$	174,850		$	163,973		$	91,821
	Asia Pacific 2		19,081			28,031			28,213
	Europe (including Israel)		27,849			25,521			9,994
	South America		2,884			3,126			2,054
		$	224,664		$	220,651		$	132,082
	1 United States	$	112,635		$	135,950		$	75,341
	1 Canada	$	62,215		$	28,023		$	16,480
	2  Japan	$	11,556		$	21,134		$	25,924
	For the years ended December 31, 2013, 2012 and 2011, long-lived assets by geographic area were as follows:
		Year Ended December 31,
		2013			2012			2011
	North America	$	9,119		$	5,772		$	4,496
	Asia Pacific		-			-			-
	Europe (including Israel)		1,370			987			828
	South America		-			-			-
		$	10,489		$	6,759		$	5,324

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited) [Abstract]	'
Schedule of Quarterly Financial Information	'
	Quarterly Financial Data (Unaudited):
		For the Quarter Ended
	2013	Mar. 31		Jun. 30			Sep. 30		Dec. 31
	Revenues	$	57,216	$	58,065		$	45,893	$	63,490
	Gross profit		45,350		46,675			36,827		50,777
	Net income		7,212		7,094			886		3,185
	Net income per share:
	Basic	$	0.35	$	0.34		$	0.04	$	0.16
	Diluted	$	0.34	$	0.34		$	0.04	$	0.16
	Shares used in computing net income per share:
	Basic		20,678,023		20,573,048			19,982,967		19,400,341
	Diluted		21,147,583		21,033,349			20,441,262		19,602,611
	2012	Mar. 31		Jun. 30			Sep. 30		Dec. 31
	Revenues	$	50,273	$	58,906		$	56,681	$	54,791
	Gross profit		39,039		46,551			45,400		43,019
	Net income		4,857		4,213			7,525		5,894
	Net income per share:
	Basic	$	0.26	$	0.2		$	0.35	$	0.28
	Diluted	$	0.26	$	0.2		$	0.35	$	0.27
	Shares used in computing net income per share:
	Basic		18,339,977		20,547,244			21,205,675		20,947,985
	Diluted		18,876,163		21,034,814			21,752,845		21,356,819
	2011	Mar. 31		Jun. 30			Sep. 30		Dec. 31
	Revenues	$	34,741	$	33,847		$	34,745	$	28,749
	Gross profit		28,519		28,157			26,603		22,507
	Net income (loss)		8,085		(10,045	)		4,249		(2,983	)
	Net income (loss) per share:
	Basic	$	0.79	$	(0.98	)	$	0.34	$	(0.22	)
	Diluted	$	0.68	$	(0.98	)	$	0.32	$	(0.22	)
	Shares used in computing net income (loss) per share:
	Basic		10,256,364		10,256,364			12,341,723		13,509,866
	Diluted		11,819,587		10,256,364			13,182,818		13,509,866

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Valuation and Qualifying Accounts	'
	Valuation and Qualifying Accounts:
					Additions Charged to
			Balance at		Cost and		Other		Deductions (2)			Balance at End
			Beginning		Expenses		Accounts (1)					of Period
	Description		of Period
	For The Year Ended December 31, 2013:
	Reserve for Doubtful Accounts		$	6,917	$	5,958	$	-	$	(2,141	)	$	10,734
	Reserve for Sales Returns		$	11,901	$	47,914	$	-	$	( 43,770	)	$	16,045
	For The Year Ended December 31, 2012:
	Reserve for Doubtful Accounts		$	3,196	$	4,629	$	-	$	( 908	)	$	6,917
	Reserve for Sales Returns		$	6,143	$	43,284	$	-	$	( 37,526	)	$	11,901
	For The Year Ended December 31, 2011:
	Reserve for Doubtful Accounts		$	1,824	$	2,595	$	70	$	(1,293	)	$	3,196
	Reserve for Sales Returns		$	3,406	$	26,610	$	-	$	( 23,873	)	$	6,143
	(1)	Represents additions due to the reverse merger on December 13, 2011.
	(2)	Represents write-offs of specific accounts receivable and actual returns.

The_Company_and_Summary_of_Sig3

The Company and Summary of Significant Accounting Policies (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Channel

Segment

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective date of merger

'

'

'

'

'

'

'

'

'

'

'

'

13-Dec-11

'

'

Number of operating segments

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

Cash and Cash Equivalents [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short term investment maturity period

'

'

'

'

'

'

'

'

'

'

'

'

'3 months

'

'

Accounts Receivable [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts receivable minimum maturity period

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

Accounts Receivable maximum maturity period

'

'

'

'

'

'

'

'

'

'

'

'

'90 days

'

'

Property and Equipment [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful life

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

Other Intangible Assets [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other intangible assets useful lives

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

Activity in warranty accrual [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrual at beginning of year

'

'

'

$1,440

'

'

'

$1,661

'

'

'

'

$1,440

$1,661

'

Additions charged to warranty expense

'

'

'

'

'

'

'

'

'

'

'

'

1,206

1,497

'

Expiring warranties

'

'

'

'

'

'

'

'

'

'

'

'

-410

-442

'

Claims satisfied

'

'

'

'

'

'

'

'

'

'

'

'

-1,085

-1,276

'

Total

1,151

'

'

'

1,440

'

'

'

1,661

'

'

'

1,151

1,440

1,661

Less: current portion

-1,094

'

'

'

-1,274

'

'

'

'

'

'

'

-1,094

-1,274

'

Long term accrued warranty

57

'

'

'

166

'

'

'

'

'

'

'

57

166

'

Liability for Employee Rights Upon Retirement [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of monthly salary eligible by employee for each year of service as severance pay

'

'

'

'

'

'

'

'

'

'

'

'

'1 month

'

'

Severance expenses

'

'

'

'

'

'

'

'

'

'

'

'

201

179

185

Revenue Recognition [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of distribution channels

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

Period of sales deferred

'

'

'

'

'

'

'

'

'

'

'

'

'14 days

'

'

Advertising Costs [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advertising expenses

'

'

'

'

'

'

'

'

'

'

'

'

71,992

60,651

32,303

Derivatives [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance of derivative instruments

255

'

'

'

402

'

'

'

'

'

'

'

255

402

'

Amount recognized as financing income

'

'

'

'

'

'

'

'

'

'

'

'

699

289

'

Notional amounts of foreign currency derivatives

6,725

'

'

'

8,400

'

'

'

'

'

'

'

6,725

8,400

'

Income Taxes [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income tax benefit percentage realized on examination (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

Weighted average number of common and common equivalent shares outstanding [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Basic number of common shares outstanding (in shares)

19,400,341

19,982,967

20,573,048

20,678,023

20,947,985

21,205,675

20,547,244

18,339,977

13,509,866

12,341,723

10,256,364

10,256,364

20,454,970

20,355,520

11,602,049

Dilutive effect of stock options and warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

202,270

408,834

0

Diluted number of common and common stock equivalent shares outstanding (in shares)

19,602,611

20,441,262

21,033,349

21,147,583

21,356,819

21,752,845

21,034,814

18,876,163

13,509,866

13,182,818

10,256,364

11,819,587

20,657,240

20,764,354

11,602,049

Common stock options and warrants excluded from computation of diluted earnings per share (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

2,172,745

1,920,442

1,791,788

Impairment of Long-Lived Assets and Intangibles [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset impairment

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

Core technology [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent costs and licensed technologies useful life

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

Product technology [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent costs and licensed technologies useful life

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

Minimum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent costs and licensed technologies useful life

'

'

'

'

'

'

'

'

'

'

'

'

'8 years

'

'

Warranty on Product Sales [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of warranty on product sales

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

Extended period of warranty on domestic sale of laser equipment

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

Maximum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent costs and licensed technologies useful life

'

'

'

'

'

'

'

'

'

'

'

'

'12 years

'

'

Warranty on Product Sales [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of warranty on product sales

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

Extended period of warranty on domestic sale of laser equipment

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

Computer Equipment [Member] | Minimum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property and Equipment [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful life

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

Computer Equipment [Member] | Maximum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property and Equipment [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful life

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

Minimum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short-term Deposits [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short-term deposits maturity period

'

'

'

'

'

'

'

'

'

'

'

'

'3 months

'

'

Maximum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short-term Deposits [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short-term deposits maturity period

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

PhotoMedex, Inc. [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of ownership on reverse merger (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

LK Technology [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective date of merger

'

'

'

'

'

'

'

'

'

'

'

'

1-Jul-13

'

'

Percentage of shares acquired by wholly-owned subsidiary (in hundredths)

100.00%

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

Radiancy, Inc. [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of ownership on reverse merger (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

Acquisition_Details

Acquisition (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2012	Dec. 13, 2011
Acquisition [Abstract]	'	'	'	'
Common stock issued after giving effect to merger (in shares)	18,903,245	'	21,043,947	18,820,852
Common stock outstanding after giving effect to merger (in shares)	18,903,245	'	21,043,947	18,820,852
Business Acquisition [Line Items]	'	'	'	'
Effective date of merger	13-Dec-11	'	'	'
Total amount of consideration	$82,562	'	'	'
Consideration transferred in cash	20,000	'	'	'
Amount of debt assumed	1,842	'	'	'
Fair value of the assets acquired and liabilities assumed [Abstract]	'	'	'	'
Market price of pre-merged PhotoMedex Shares (in dollars per share)	$15.60	'	'	'
Consideration transferred in cash	20,000	'	'	'
Change in valuation on unvested restricted stock	'	1,353	'	'
Summarized combined result after giving effect acquisition adjustments [Abstract]	'	'	'	'
Net revenues	'	162,341	'	'
Net income (loss)	'	-13,077	'	'
Net income (loss) per share: [Abstract]	'	'	'	'
Basic (in dollars per share)	'	($0.91)	'	'
Diluted (in dollars per share)	'	($0.91)	'	'
Shares used in calculating net income (loss) per share [Abstract]	'	'	'	'
Basic (in shares)	'	14,445,184	'	'
Diluted (in shares)	'	14,445,184	'	'
PhotoMedex, Inc. [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Percentage of ownership on reverse merger (in hundredths)	20.00%	'	'	'
Percentage of ownership agreed on reverse merger (in hundredths)	25.00%	'	'	'
Radiancy, Inc. [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Percentage of ownership on reverse merger (in hundredths)	80.00%	'	'	'
Percentage of ownership agreed on reverse merger (in hundredths)	75.00%	'	'	'
LK Technology [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Effective date of merger	1-Jul-13	'	'	'
Percentage of shares acquired by wholly-owned subsidiary (in hundredths)	100.00%	'	'	'
Total consideration	100	'	'	'
Estimated profit	81	'	'	'
Total amount of consideration	181	'	'	'
Consideration transferred in cash	41	'	'	'
Cash down payment	59	'	'	'
Fair value of the assets acquired and liabilities assumed [Abstract]	'	'	'	'
Cash and cash equivalents	125	'	'	'
Accounts receivable	1	'	'	'
Inventories	20	'	'	'
Prepaid expenses and other current assets	2	'	'	'
Total assets acquired at fair value	148	'	'	'
Accounts payable	-75	'	'	'
Accrued compensation and related expenses	-2	'	'	'
Other accrued liabilities	-11	'	'	'
Total liabilities assumed	-88	'	'	'
Net assets acquired	60	'	'	'
Consideration transferred in cash	$41	'	'	'

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of inventories [Abstract]	'	'
Raw materials and work-in-process	$12,631	$9,012
Finished goods	14,916	13,455
Total inventories	$27,547	$22,467

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	$18,568	$12,329	'
Accumulated depreciation and amortization	-8,079	-5,570	'
Total property and equipment, net	10,489	6,759	'
Depreciation and related amortization expense	2,875	2,367	356
Lasers-in-service [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	12,599	7,301	'
Equipment, Computer Hardware and Software [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	4,730	4,015	'
Furniture and Fixtures [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	705	617	'
Leasehold Improvements [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	$534	$396	'

Patents_and_Licensed_Technolog2

Patents and Licensed Technologies, net (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Patents and Licensed Technologies [Abstract]	'	'	'
Net Book Value	$10,832	$12,673	'
Amortization expense	2,043	2,049	184
Estimated amortization expense for amortizable patents and licensed technologies assets [Abstract]	'	'	'
Net Book Value	10,832	12,673	'
Patents [Member]	'	'	'
Patents and Licensed Technologies [Abstract]	'	'	'
Product and core technologies under purchase price allocation	13,500	'	'
Patents and Licensed Technologies [Member]	'	'	'
Patents and Licensed Technologies [Abstract]	'	'	'
Gross Amount beginning of period	15,411	15,124	'
Additions	171	181	'
Translation differences	66	106	'
Gross Amount end of period	15,648	15,411	'
Accumulated amortization	-4,816	-2,738	'
Net Book Value	10,832	12,673	'
Estimated amortization expense for amortizable patents and licensed technologies assets [Abstract]	'	'	'
2014	2,052	'	'
2015	2,045	'	'
2016	2,040	'	'
2017	905	'	'
2018	905	'	'
Thereafter	2,885	'	'
Net Book Value	$10,832	$12,673	'

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill [Roll Forward]	'	'	'
Goodwill, beginning balance	$24,500	'	'
Additions to goodwill	121	'	'
Translation differences	309	'	'
Goodwill, ending balance	24,930	24,500	'
Accumulated impairment loss	0	'	'
Schedule of definite-lived intangible assets [Abstract]	'	'	'
Gross Amount	12,116	12,000	'
Translation differences	73	116	'
Gross Amount	12,189	12,116	12,000
Accumulated Amortization	-2,488	-1,262	'
Net Book Value	9,701	10,854	'
Amortization expense	1,200	1,212	50
Estimated amortization expense for amortizable intangible assets [Abstract]	'	'	'
2014	1,200	'	'
2015	1,200	'	'
2016	1,200	'	'
2017	1,200	'	'
2018	1,200	'	'
Thereafter	3,701	'	'
Net Book Value	9,701	10,854	'
Trademarks [Member]	'	'	'
Schedule of definite-lived intangible assets [Abstract]	'	'	'
Gross Amount	5,744	5,700	'
Translation differences	28	44	'
Gross Amount	5,772	5,744	'
Accumulated Amortization	-1,178	-598	'
Net Book Value	4,594	5,146	'
Estimated amortization expense for amortizable intangible assets [Abstract]	'	'	'
Net Book Value	4,594	5,146	'
Customer Relationships [Member]	'	'	'
Schedule of definite-lived intangible assets [Abstract]	'	'	'
Gross Amount	6,372	6,300	'
Translation differences	45	72	'
Gross Amount	6,417	6,372	'
Accumulated Amortization	-1,310	-664	'
Net Book Value	5,107	5,708	'
Estimated amortization expense for amortizable intangible assets [Abstract]	'	'	'
Net Book Value	5,107	5,708	'
Radiancy, Inc. [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Definite-lived intangible assets recorded as a part of purchase price allocation	12,000	'	'
Consumer Segment [Member]	'	'	'
Goodwill [Roll Forward]	'	'	'
Goodwill, ending balance	20,850	'	'
Physician Recurring Segment [Member]	'	'	'
Goodwill [Roll Forward]	'	'	'
Goodwill, ending balance	$4,080	'	'

Accrued_Compensation_and_relat2

Accrued Compensation and related expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Compensation and related expenses [Abstract]	'	'
Accrued payroll and related taxes	$707	$1,010
Accrued vacation	290	262
Accrued commissions and bonus	2,233	1,222
Total accrued compensation and related expense	$3,230	$2,494

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Other Accrued Liabilities [Abstract]	'		'
Accrued warranty, current, see Note 1	$1,094		$1,274
Accrued taxes, including liability for unrecognized tax benefit, see Note 12	1,023		4,304
Accrued sales return (1)	16,046	[1]	11,901	[1]
Other accrued liabilities	3,869		4,620
Total other accrued liabilities	22,032		22,099
Balance at beginning of year	11,901	[1]	6,143
Additions that reduce net sales	47,916		43,284
Actual returns	-43,771		-37,526
Balance at end of period	$16,046	[1]	$11,901	[1]
[1]	The activity in the sales returns liability account was as follows: December 31, 20122011 Balance at beginning of year$6,143$3,406 Additions that reduce net sales43,28426,610 Deductions from reserves(37,526)(23,873) Balance at end of year$11,901$6,143

Shortterm_Debt_Details

Short-term Debt (Details) (Term-Note Facility [Member], USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2013	Feb. 03, 2014	Dec. 31, 2013	Dec. 31, 2013
		Subsequent Event [Member]	LIBOR [Member]	Federal [Member]
Debt Instrument [Line Items]	'	'	'	'
Maximum borrowing capacity	$15,000,000	'	'	'
Period for term note facility (in years)	'1 year	'	'	'
Total borrowings	10,000,000	'	'	'
Effective interest rate (in hundredths)	'	'	0.50%	2.50%
Description of variable rate basis	'LIBOR plus 2.5%.	'	'	'
Repayment of entire balance	'	$10,000,000	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Lease
Commitments and Contingencies [Abstract]	'	'	'
Number of minority operating lease	1	'	'
Rent expense	$1,002	$908	$458
Annual minimum payments under operating lease [Abstract]	'	'	'
2014	535	'	'
2015	336	'	'
2016	56	'	'
Thereafter	0	'	'
Total	927	'	'
Amount of aggregate commitment under the executive severance agreements should all covered executives and employees be terminated other than for cause	1,427	'	'
Amount of commitment should all covered executives and certain key employees be terminated following a change in control of the Company	$1,174	'	'

Stockholders_Equity_Details

Stockholders Equity (Details) (USD $)

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 13, 2011

Dec. 12, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 18, 2012

Aug. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2011

Dec. 31, 2011

Jun. 30, 2011

Dec. 31, 2013

Feb. 28, 2013

Mar. 18, 2012

Dec. 31, 2013

Jan. 26, 2012

Dec. 31, 2013

Feb. 28, 2013

Mar. 18, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 13, 2011

Dec. 13, 2011

Dec. 31, 2013

Dec. 31, 2011

Jul. 04, 2011

Mar. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

$0 - $15.00 [Member]

$15.01 - $30.00 [Member]

$30.01 - $45.00 [Member]

$45.01 - $60.00 [Member]

$60.01 - up [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Executives employees [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Directors, executives and employees [Member]

Directors, executives and employees [Member]

Employees and Consultants [Member]

Employees and Consultants [Member]

Plan [Member]

Non-employee director stock option plan [Member]

Non-employee director stock option plan [Member]

Non-qualified member [Member]

Non-qualified member [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

PhotoMedex, Inc. [Member]

PhotoMedex, Inc. [Member]

Radiancy, Inc. [Member]

Radiancy, Inc. [Member]

Minimum [Member]

Maximum [Member]

Employee

Executives employees [Member]

Executives employees [Member]

Executives employees [Member]

Executives employees [Member]

Executives employees [Member]

Executives employees [Member]

Executives employees [Member]

Non-employee director stock option plan [Member]

2005 Equity Plan [Member]

Plan [Member]

Stock Options [Member]

Stock Options [Member]

Employee

Employee

Executive

Preferred Stock [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, par value (in dollars per share)

$0.01

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, authorized (in shares)

5,000,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, outstanding (in shares)

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchase program, authorized amount

'

'

'

'

'

'

'

'

'

'

$25,000,000

$30,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchased during period (in shares)

'

'

16,056

'

'

'

'

'

'

'

'

'

2,987,413

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchased average price (in dollars per share)

$13.98

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchased during period

41,757,000

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, authorized (in shares)

50,000,000

50,000,000

'

'

35,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, issued (in shares)

18,903,245

21,043,947

'

18,820,852

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,084,370

'

'

'

Reverse merger acquisition (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

380,000

'

'

'

'

'

'

'

'

'

'

'

Number of executive employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

2

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,928

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Options [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for grant (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,033,748

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Award vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'3 years

'

'

'5 years

'5 years

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'

'

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

Authorized shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

120,000

3,000,000

'

'

'

'

Stock reserved for issuance to eligible employees (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares reserved for future issuance under stock option (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,077,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,115,601,000

'

'

'

'

One time stock issuance after reverse merger (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

Shares reserved for future issuance under common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

753,095

'

'

'

'

Number of Stock Options [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, beginning of the period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

898,541

180,718

1,950,936

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,045,571

'

732,292

'

177,125

509,000

'

'

'

82,500

230,000

259,625

739,000

1,476,279

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,740,414

'

'

'

'

'

'

'

-3,750

-10,048

-2,782,435

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumed in reverse merger (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

180,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expired/cancelled (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-21,738

-11,129

-644,780

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, ending of the period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,132,678

898,541

180,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding and Exercisable, at ending period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

320,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, beginning period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16.65

$19.54

$0.69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16.59

$15.87

$0.04

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.24

$6.67

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumed in reverse merger (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19.54

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expired/cancelled (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$31.36

$20.25

$1.32

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, ending period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16.51

$16.65

$19.54

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding and Exercisable, ending period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

$17.35

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014 (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,499

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015 (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,499

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016 (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,634

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017 (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,146

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018 and later (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,121,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,132,678

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$102.48

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$102.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$69.48

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$46.85

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018 and later (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.91

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16.51

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$102.48

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$102.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$48.72

$93.66

2017 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$46.62

$47.88

2018 and later (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.70

$20

Exercise Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.70

$102.90

Black-Scholes option-pricing model to estimate fair value of grants of stock options [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.30%

1.20%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Volatility (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.25%

85.53%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected life (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years 6 months

'5 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated forfeiture rate (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12.95

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

405,000

'

2,590,000

6,652,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Strike price options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15

$14

'

'

'

$20

$20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price of common stock eligible to be repurchased (in dollars per share)

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

Unvested stock awards assumed during reverse acquisition (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

164,000

'

'

'

'

'

'

'

'

'

Shares awarded by Pre-merged PhotoMedex (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

Number of senior executives

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Stock awards vested (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49,470

'

'

'

'

'

'

'

'

'

'

'

'

'

36,000

'

'

'

'

'

'

'

'

'

'

'

'

Expiration period of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Total stock-based compensation expense

4,985,000

6,197,000

34,001,000

'

'

'

'

'

'

'

'

'

'

'

'

27,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Bonus

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option exercise price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

$17.35

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option exercisable to shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option exercisable to shares (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$13.62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option vested (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option vesting date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Jun-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options vest on condition (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

616,155

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option vesting percentage (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining option vesting condition (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining option vest in consecutive quarter (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock eligible to be repurchased (in shares)

66,912

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price of common stock eligible to be repurchased (in dollars per share)

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation relating to options exercised by Board of Directors pursuant to reverse merger

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to non-vested stock awards

$8,569,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost expected to recognized

'2 years 9 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued (in shares)

0.305836

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants (in shares)

1,026,435

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price (in dollars per share)

$20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise period

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum closing trading price (in dollars per share)

$30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consecutive trading days

'20 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, Beginning Balance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,063,268

1,067,240

0

'

'

'

'

'

'

Issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

25,000

0

'

'

'

'

'

'

Assumed in reverse merger (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,067,240

'

'

'

'

'

'

Exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

-17,756

0

'

'

'

'

'

'

Expired/cancelled (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,589

-11,216

0

'

'

'

'

'

'

Outstanding, Ending Balance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,058,679

1,063,268

1,067,240

'

'

'

'

'

'

Weighted Average Exercise Price [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, Beginning Balance (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19.91

$19.98

$0

'

'

'

'

'

'

Issued (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$20

$0

'

'

'

'

'

'

Assumed in reverse merger (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19.98

'

'

'

'

'

'

Exercised (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$7.50

$0

'

'

'

'

'

'

Expired/cancelled

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$18.48

$47.04

$0

'

'

'

'

'

'

Outstanding, Ending Balance (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19.91

$19.91

$19.98

'

'

'

'

'

'

Number of Warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014 (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,026,429

'

'

'

'

'

'

'

'

2015 (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,250

'

'

'

'

'

'

'

'

Number of Warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,058,679

1,063,268

1,067,240

'

'

'

'

'

'

Weighted Average Exercise Price [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20

'

'

'

'

'

'

'

'

2015 (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$17.19

'

'

'

'

'

'

'

'

Weighted Average Exercise Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19.91

$19.91

$19.98

'

'

'

'

'

'

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options Range of Exercise Prices, lower limit (in dollars per share)

'

'

'

'

'

$0

$15.01

$30.01

$45.01

$60.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options Range of Exercise Prices, upper limit (in dollars per share)

'

'

'

'

'

$15

$30

$45

$60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding Number of Shares (in shares)

1,132,678

'

'

'

'

691,831

427,900

2,169

3,563

7,215

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Remaining Contractual Life (years)

'8 years 3 months

'

'

'

'

'8 years 3 months 29 days

'8 years 3 months 25 days

'4 years 0 months 7 days

'2 years 11 months 19 days

'1 year 0 months 11 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price (in dollars per share)

$16.51

'

'

'

'

$13.92

$19.02

$39.41

$47.07

$93.69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable Number of Shares (in shares)

320,053

'

'

'

'

145,706

161,400

2,169

3,563

7,215

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable Weighted Avg. Exercise Price (in dollars per share)

$17.35

'

'

'

'

$12.45

$17.41

$39.41

$47.07

$93.69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income (loss) before income tax [Abstract]	'	'	'
U.S	$7,698,000	$3,152,000	($16,309,000)
Israel	14,279,000	20,414,000	13,980,000
Other Foreign	768,000	3,365,000	0
Total	22,745,000	26,931,000	-2,329,000
United States - Federal tax [Abstract]	'	'	'
Current	-1,253,000	2,752,000	246,000
Deferred	1,795,000	-1,572,000	-5,495,000
United States - State tax [Abstract]	'	'	'
Current	180,000	315,000	0
Deferred	850,000	-2,074,000	-243,000
Israel [Abstract]	'	'	'
Current	2,781,000	4,034,000	3,487,000
Deferred	-237,000	-50,000	-17,000
Other Foreign [Abstract]	'	'	'
Current	54,000	1,371,000	0
Deferred	200,000	-338,000	0
Income tax expense (benefit)	4,370,000	4,438,000	-2,022,000
Tax rate (in hundredths)	35.00%	35.00%	35.00%
Income tax expense (benefit) [Abstract]	'	'	'
Federal tax expense (benefit) at 35%	7,961,000	9,426,000	-815,000
State and local income tax	958,000	286,000	-320,000
Foreign rate differential	-2,656,000	-4,213,000	-3,654,000
Increase in taxes from permanent differences in stock-based compensation	433,000	637,000	2,674,000
US taxation of foreign earnings - Subpart F	367,000	403,000	0
Increase (decrease) in uncertain tax positions	269,000	-2,325,000	0
Return to provision and other adjustments	-1,964,000	0	0
Impact of tax rate change on deferred taxes	-942,000	0	0
Foreign tax credits	-341,000	0	0
Change in valuation allowance	116,000	0	0
Other	169,000	224,000	93,000
Income tax expense (benefit)	4,370,000	4,438,000	-2,022,000
Operating Loss Carryforwards [Line Items]	'	'	'
Loss carryforwards recognized in the deferred tax account	21,092,000	20,122,000	'
Photo Therapeutics Ltd [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
Operating Loss Carryforwards	11,000,000	'	'
Israeli subsidiary [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
Income tax examination	'2010 through 2013	'	'
Brazilian Subsidiary [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
Operating Loss Carryforwards	300,000	'	'
Federal [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
Operating Loss Carryforwards	48,000,000	'	'
Income tax examination	'2010 through 2013	'	'
Loss carryforwards recognized in the deferred tax account	18,400,000	'	'
State and Local Jurisdiction [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
Deferred tax asset	1,971	'	'
Income tax examination	'2005 through 2013	'	'
Operating loss carryforwards, valuation allowance	$1,548	'	'
Operating loss carryforwards expiration	'through 2017 to 2033	'	'

Income_Taxes_Tax_Carryforward_

Income Taxes, Tax Carryforward and Other (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Components of Deferred Tax Assets and Liabilities [Abstract]	'	'
Loss carryforwards	$21,092	$20,122
AMT credits	112	1,495
Foreign tax credits	0	446
Accrued employment expenses	1,256	718
Amortization and write-offs	8,883	10,557
Capitalized R&D costs	2,933	3,670
Deferred revenues	84	301
Depreciation	4,360	5,537
Doubtful accounts	3,499	2,121
Inventory reserves	822	0
Other accruals and reserves	228	617
Return allowances	5,660	4,118
Translation adjustments	61	0
Gross deferred tax asset	48,990	49,702
Less: valuation allowance	-11,910	-10,075
Net deferred tax asset	37,080	39,627
Among current assets	13,041	19,441
Among other non-current assets	24,039	20,186
Federal [Member]	'	'
Components of Deferred Tax Assets and Liabilities [Abstract]	'	'
Loss carryforwards	$18,400	'

Income_Taxes_Income_Taxes_cont

Income Taxes, Income Taxes continued (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income taxes [Line Items]	'	'	'
Corporate tax rate pursuant to Law for the Change in the Tax Burden (in hundredths)	25.00%	'	'
Tax Benefits Under Law of Encouragements [Abstract]	'	'	'
Tax exempt period	'2 years	'	'
Accelerated depreciation period	'5 years	'	'
Unrecognized tax benefits	$0	'	'
Rate at which subsidiary earnings are taxed (in hundredths)	35.00%	35.00%	35.00%
Reconciliation of unrecognized tax benefits [Roll Forward]	'	'	'
Beginning balance	375	2,700	2,700
Additions / Settlements	269	-2,325	0
Ending balance	$644	$375	$2,700
Minimum [Member]	'	'	'
Tax Benefits Under Law of Encouragements [Abstract]	'	'	'
Reduction of income tax rates (in years)	'7 years	'	'
Succeeding tax exempt period	'5 years	'	'
Maximum [Member]	'	'	'
Tax Benefits Under Law of Encouragements [Abstract]	'	'	'
Reduction of income tax rates (in years)	'10 years	'	'
Succeeding tax exempt period	'8 years	'	'
Israeli subsidiary [Member]	'	'	'
Tax Benefits Under Law of Encouragements [Abstract]	'	'	'
Tax exempt rate (in hundredths)	15.00%	'	'
Israeli subsidiary [Member] | Current Period [Member]	'	'	'
Tax Benefits Under Law of Encouragements [Abstract]	'	'	'
Preferred income tax rate (in hundredths)	'	15.00%	'
Standard corporate income tax rate (in hundredths)	'	25.00%	'
Israeli subsidiary [Member] | Prospective [Member]	'	'	'
Tax Benefits Under Law of Encouragements [Abstract]	'	'	'
Preferred income tax rate (in hundredths)	16.00%	'	'
Standard corporate income tax rate (in hundredths)	26.50%	'	'
United Kingdom Tax Authority [Member]	'	'	'
Tax Benefits Under Law of Encouragements [Abstract]	'	'	'
Rate at which subsidiary earnings are taxed (in hundredths)	24.00%	23.00%	'

Significant_Customer_Concentra1

Significant Customer Concentration (Details) (Ya-Man [Member])	12 Months Ended
	Dec. 31, 2011
Ya-Man [Member]	'
Revenue, Major Customer [Line Items]	'
Percentage of revenue generated by single major customer (in hundredths)	20.00%

Business_Segments_and_Geograph

Business Segments and Geographic Data (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Segment

Business Segment and Geographic Data [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of operating segments

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

Results of operations from business segments [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

$63,490

$45,893

$58,065

$57,216

$54,791

$56,681

$58,906

$50,273

$28,749

$34,745

$33,847

$34,741

$224,664

$220,651

$132,082

Cost of revenues

'

'

'

'

'

'

'

'

'

'

'

'

45,035

46,642

26,296

Gross profit

50,777

36,827

46,675

45,350

43,019

45,400

46,551

39,039

22,507

26,603

28,157

28,519

179,629

174,009

105,786

Gross profit % (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

78.90%

80.10%

Allocated operating expenses [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Engineering and product development

'

'

'

'

'

'

'

'

'

'

'

'

3,306

2,914

1,057

Selling and marketing expenses

'

'

'

'

'

'

'

'

'

'

'

'

127,528

116,487

62,185

Unallocated operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

26,750

27,330

45,192

Total operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

157,584

146,731

108,434

Operating profit (loss)

'

'

'

'

'

'

'

'

'

'

'

'

22,045

27,278

-2,648

Interest and other financing income (expense), net

'

'

'

'

'

'

'

'

'

'

'

'

702

-351

-68

Net income (loss) before taxes

'

'

'

'

'

'

'

'

'

'

'

'

22,747

26,927

-2,716

CONSUMER [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Results of operations from business segments [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

188,259

188,425

125,581

Cost of revenues

'

'

'

'

'

'

'

'

'

'

'

'

26,794

28,965

23,309

Gross profit

'

'

'

'

'

'

'

'

'

'

'

'

161,465

159,460

102,272

Gross profit % (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

85.80%

84.60%

81.40%

Allocated operating expenses [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Engineering and product development

'

'

'

'

'

'

'

'

'

'

'

'

1,100

876

837

Selling and marketing expenses

'

'

'

'

'

'

'

'

'

'

'

'

112,898

102,736

59,424

Unallocated operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

Total operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

113,998

103,612

60,261

Operating profit (loss)

'

'

'

'

'

'

'

'

'

'

'

'

47,467

55,848

42,011

Interest and other financing income (expense), net

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

Net income (loss) before taxes

'

'

'

'

'

'

'

'

'

'

'

'

47,467

55,848

42,011

PHYSICIAN RECURRING [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Results of operations from business segments [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

28,548

21,284

829

Cost of revenues

'

'

'

'

'

'

'

'

'

'

'

'

13,022

11,512

456

Gross profit

'

'

'

'

'

'

'

'

'

'

'

'

15,526

9,772

373

Gross profit % (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

54.40%

46.00%

45.00%

Allocated operating expenses [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Engineering and product development

'

'

'

'

'

'

'

'

'

'

'

'

1,371

1,201

27

Selling and marketing expenses

'

'

'

'

'

'

'

'

'

'

'

'

12,681

10,203

319

Unallocated operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

Total operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

14,052

11,404

346

Operating profit (loss)

'

'

'

'

'

'

'

'

'

'

'

'

1,474

-1,632

27

Interest and other financing income (expense), net

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

Net income (loss) before taxes

'

'

'

'

'

'

'

'

'

'

'

'

1,474

-1,632

27

PROFESSIONAL [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Results of operations from business segments [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

7,857

10,942

5,672

Cost of revenues

'

'

'

'

'

'

'

'

'

'

'

'

5,219

6,165

2,531

Gross profit

'

'

'

'

'

'

'

'

'

'

'

'

2,638

4,777

3,141

Gross profit % (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

33.60%

43.70%

55.40%

Allocated operating expenses [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Engineering and product development

'

'

'

'

'

'

'

'

'

'

'

'

835

837

193

Selling and marketing expenses

'

'

'

'

'

'

'

'

'

'

'

'

1,949

3,548

2,442

Unallocated operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

Total operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

2,784

4,385

2,635

Operating profit (loss)

'

'

'

'

'

'

'

'

'

'

'

'

-146

392

506

Interest and other financing income (expense), net

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

Net income (loss) before taxes

'

'

'

'

'

'

'

'

'

'

'

'

($146)

$392

$506

Business_Segment_and_Geographi2

Business Segment and Geographic Data, Revenue by Geographical Data (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Net revenues by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

$63,490

$45,893

$58,065

$57,216

$54,791

$56,681

$58,906

$50,273

$28,749

$34,745

$33,847

$34,741

$224,664

$220,651

$132,082

Long-lived assets by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-lived assets

10,489

'

'

'

6,759

'

'

'

5,324

'

'

'

10,489

6,759

5,324

North America [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net revenues by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

174,850

163,973

91,821

Long-lived assets by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-lived assets

9,119

'

'

'

5,772

'

'

'

4,496

'

'

'

9,119

5,772

4,496

Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net revenues by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

19,081

28,031

28,213

Long-lived assets by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-lived assets

0

'

'

'

0

'

'

'

0

'

'

'

0

0

0

Europe (Including Israel) [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net revenues by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

27,849

25,521

9,994

Long-lived assets by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-lived assets

1,370

'

'

'

987

'

'

'

828

'

'

'

1,370

987

828

South America [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net revenues by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

2,884

3,126

2,054

Long-lived assets by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-lived assets

0

'

'

'

0

'

'

'

0

'

'

'

0

0

0

United States [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net revenues by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

112,635

135,950

75,341

Canada [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net revenues by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

62,215

28,023

16,480

Japan [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net revenues by geographic area [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

$11,556

$21,134

$25,924

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended												12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Data (Unaudited) [Abstract]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Revenues	$63,490	$45,893	$58,065	$57,216	$54,791	$56,681	$58,906	$50,273	$28,749	$34,745	$33,847	$34,741	$224,664	$220,651	$132,082
Gross profit	50,777	36,827	46,675	45,350	43,019	45,400	46,551	39,039	22,507	26,603	28,157	28,519	179,629	174,009	105,786
Net income (loss)	$3,185	$886	$7,094	$7,212	$5,894	$7,525	$4,213	$4,857	($2,983)	$4,249	($10,045)	$8,085	$18,377	$22,489	($694)
Net income (loss) per share	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Basic (in dollars per share)	$0.16	$0.04	$0.34	$0.35	$0.28	$0.35	$0.20	$0.26	($0.22)	$0.34	($0.98)	$0.79	$0.90	$1.10	($0.06)
Diluted (in dollars per share)	$0.16	$0.04	$0.34	$0.34	$0.27	$0.35	$0.20	$0.26	($0.22)	$0.32	($0.98)	$0.68	$0.89	$1.08	($0.06)
Shares used in computing net income (loss) per share:	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Basic (in shares)	19,400,341	19,982,967	20,573,048	20,678,023	20,947,985	21,205,675	20,547,244	18,339,977	13,509,866	12,341,723	10,256,364	10,256,364	20,454,970	20,355,520	11,602,049
Diluted (in shares)	19,602,611	20,441,262	21,033,349	21,147,583	21,356,819	21,752,845	21,034,814	18,876,163	13,509,866	13,182,818	10,256,364	11,819,587	20,657,240	20,764,354	11,602,049

Valuation_and_Qualifying_Accou2

Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Reserve for Doubtful Accounts [Member]	'		'		'
Movement in Valuation Allowances and Reserves [Roll Forward]	'		'		'
Beginning Balance	$6,917		$3,196		$1,824
Cost and Expense	5,958		4,629		2,595
Other Accounts	0	[1]	0	[1]	70	[1]
Deductions	-2,141	[2]	-908	[2]	-1,293	[2]
Ending Balance	10,734		6,917		3,196
Reserve for Sales Returns [Member]	'		'		'
Movement in Valuation Allowances and Reserves [Roll Forward]	'		'		'
Beginning Balance	11,901		6,143		3,406
Cost and Expense	47,914		43,284		26,610
Other Accounts	0	[1]	0	[1]	0	[1]
Deductions	-43,770	[2]	-37,526	[2]	-23,873	[2]
Ending Balance	$16,045		$11,901		$6,143
[1]	Represents additions due to the reverse merger on December 13, 2011.
[2]	Represents write-offs of specific accounts receivable and returns.

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Dec. 31, 2013	Feb. 13, 2014	Feb. 13, 2014	Feb. 13, 2014	Feb. 13, 2014
		Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
			Revolving Credit Facility [Member]	Term Loan [Member]	LCA Vision Inc [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Cash price per share (in dollars per share)	'	'	'	'	$5.37
Price per share as ownership (in dollars per share)	'	'	'	'	$5.37
Percentage of cash price per share represents closing price of common stock (in hundredths)	'	'	'	'	34.00%
Approx purchase price for all stock and equity instrument	$82,562,000	'	'	'	$106,400,000
Debt amount to fund the transaction	'	85,000,000	75,000,000	10,000,000	'
Debt instrument term (in years)	'	'	'	'4 years	'
Go shop period for merger agreement	'	'	'	'	'30 days
Merger termination fee	'	'	'	'	3,200,000
Maximum merger termination Expenses	'	'	'	'	$1,000,000